CA2421582A1 - Combinatorial fluorescence energy transfer tags and uses thereof - Google Patents
Combinatorial fluorescence energy transfer tags and uses thereof Download PDFInfo
- Publication number
- CA2421582A1 CA2421582A1 CA002421582A CA2421582A CA2421582A1 CA 2421582 A1 CA2421582 A1 CA 2421582A1 CA 002421582 A CA002421582 A CA 002421582A CA 2421582 A CA2421582 A CA 2421582A CA 2421582 A1 CA2421582 A1 CA 2421582A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- nucleic acid
- oligonucleotide
- dna
- matter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012546 transfer Methods 0.000 title claims abstract description 44
- 239000002062 molecular scaffold Substances 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims description 101
- 238000000034 method Methods 0.000 claims description 90
- 108091034117 Oligonucleotide Proteins 0.000 claims description 79
- 125000003729 nucleotide group Chemical group 0.000 claims description 77
- 102000039446 nucleic acids Human genes 0.000 claims description 62
- 108020004707 nucleic acids Proteins 0.000 claims description 62
- 150000007523 nucleic acids Chemical class 0.000 claims description 61
- 108020004414 DNA Proteins 0.000 claims description 60
- 239000000975 dye Substances 0.000 claims description 54
- 239000002773 nucleotide Substances 0.000 claims description 42
- 229910019142 PO4 Inorganic materials 0.000 claims description 33
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 29
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 29
- 239000010452 phosphate Substances 0.000 claims description 29
- 239000007850 fluorescent dye Substances 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 27
- 239000005546 dideoxynucleotide Substances 0.000 claims description 25
- 238000000295 emission spectrum Methods 0.000 claims description 20
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 16
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 16
- 230000005284 excitation Effects 0.000 claims description 16
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical group C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims description 15
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical group CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 14
- 230000005855 radiation Effects 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 12
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 12
- 229960002685 biotin Drugs 0.000 claims description 11
- 239000011616 biotin Substances 0.000 claims description 11
- 102000012410 DNA Ligases Human genes 0.000 claims description 10
- 108010061982 DNA Ligases Proteins 0.000 claims description 10
- 238000006116 polymerization reaction Methods 0.000 claims description 9
- 108010090804 Streptavidin Proteins 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 239000002096 quantum dot Substances 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 238000009396 hybridization Methods 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 claims description 6
- 239000001226 triphosphate Substances 0.000 claims description 6
- 235000011178 triphosphate Nutrition 0.000 claims description 6
- HBROZNQEVUILML-UHFFFAOYSA-N salicylhydroxamic acid Chemical compound ONC(=O)C1=CC=CC=C1O HBROZNQEVUILML-UHFFFAOYSA-N 0.000 claims description 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 4
- XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 claims description 3
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 claims description 3
- 229920000388 Polyphosphate Polymers 0.000 claims description 3
- OTXOHOIOFJSIFX-POYBYMJQSA-N [[(2s,5r)-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)O)CC[C@@H]1N1C(=O)NC(=O)C=C1 OTXOHOIOFJSIFX-POYBYMJQSA-N 0.000 claims description 3
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 claims description 3
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 claims description 3
- 239000001205 polyphosphate Substances 0.000 claims description 3
- 235000011176 polyphosphates Nutrition 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 abstract description 26
- 239000013615 primer Substances 0.000 description 71
- 102000053602 DNA Human genes 0.000 description 56
- 239000000047 product Substances 0.000 description 39
- 230000035772 mutation Effects 0.000 description 28
- 235000021317 phosphate Nutrition 0.000 description 25
- 210000000349 chromosome Anatomy 0.000 description 24
- 238000013459 approach Methods 0.000 description 19
- 238000001514 detection method Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 125000006850 spacer group Chemical group 0.000 description 17
- 239000000370 acceptor Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000001962 electrophoresis Methods 0.000 description 12
- 238000011161 development Methods 0.000 description 10
- 238000001712 DNA sequencing Methods 0.000 description 9
- 201000000582 Retinoblastoma Diseases 0.000 description 9
- 238000010276 construction Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 101150002130 Rb1 gene Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 208000036878 aneuploidy Diseases 0.000 description 7
- 231100001075 aneuploidy Toxicity 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000007834 ligase chain reaction Methods 0.000 description 5
- 150000008300 phosphoramidites Chemical class 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 4
- 206010064571 Gene mutation Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- 238000001215 fluorescent labelling Methods 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- ZOADTRDGOSLUFJ-BYPYZUCNSA-N (2s)-1-azidopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1N=[N+]=[N-] ZOADTRDGOSLUFJ-BYPYZUCNSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002559 cytogenic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 238000003800 Staudinger reaction Methods 0.000 description 2
- 229910052771 Terbium Inorganic materials 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical class [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 108060006184 phycobiliprotein Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003147 proline derivatives Chemical class 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LFRDGHVRPSURMV-YFKPBYRVSA-N (4s)-4,5-dihydroxypentanal Chemical compound OC[C@@H](O)CCC=O LFRDGHVRPSURMV-YFKPBYRVSA-N 0.000 description 1
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- KBDWGFZSICOZSJ-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1H-pyrimidin-4-one Chemical compound N1CNC=C(C1=O)C KBDWGFZSICOZSJ-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 0 CC(C1)*1NN Chemical compound CC(C1)*1NN 0.000 description 1
- 101710184216 Cardioactive peptide Proteins 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 208000025939 DNA Repair-Deficiency disease Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101900234631 Escherichia coli DNA polymerase I Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000000039 Heat Shock Transcription Factor Human genes 0.000 description 1
- 108050008339 Heat Shock Transcription Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000033321 ICF syndrome Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- -1 NHS ester Chemical class 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000033787 Rare developmental defect during embryogenesis Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 101900178114 Thermoplasma acidophilum Inorganic pyrophosphatase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000022734 developmental defect during embryogenesis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 208000004731 long QT syndrome Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 208000035853 malformation syndrome Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Mathematical Physics (AREA)
- Theoretical Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
This invention provides a combinatorial fluorescence energy transfer tag whi ch comprises a plurality of fluorescent molecules, comprising one or more energ y transfer donor and one or more energy transfer acceptor, linked through a molecular scaffold wherein the fluorescent molecules are separated along the scaffold to produce a unique fluorescene emission signature. The invention further provides for the use of said tags in multi-component analyses, including multiplex biological analyses.
Description
COMBINATORIAL FLUORESCENCE ENERGY TRANSFER TAGS AND
USES THEREOF
This application claims priority of Provisional Application no. 60/309,156, filed July 31, 2001 and is a continuation in part of U.S. Serial No.
09/658,077, filed September 11, 2000, the contents of both of which are hereby incorporated by reference into the subject application.
Throughout this application, various publications are referenced in parentheses by author and year. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
Background Of The Invention The need to study many biological targets simultaneously drives the development of multiplex fluorescent tags. However, due to the limits of the spectral region, and therefore the availability of appropriate detectors, the number of available fluorescent dyes that have distinguishable emission spectra is limited to about ten. To overcome this limitation, a combinatorial fluorescent labeling approach for multi-color fluorescence in situ hybridization (M-FISH) has been developed and is now widely used in the field of cytogenetics (Speicher et al., 1996; Schrock et ai., 1996). This approach mixes from two to seven individual fluorescent dyes that have unique emissions, and uses the fluorescence emission pattern to identify the different targets.
The unique fluorescence emission pattern is achieved by mathematically combining the different dyes. This development has made possible advances in chromosome analyses. However, the procedure requires physically mixing the individual dyes in a quantitative manner to develop "unique" probe labels. This requirement, coupled with the potential interactions of the dyes, complicates the fluorescence emission patterns.
Therefore, the major application of the technique is limited to methods that involve hybridization.
Multiple lasers and detectors are also required for the imaging. A reagent kit that can be used to covalently label a wide range of biomolecules is difficult to construct with this approach. Thus, there is an urgent need for a large set of fluorescent tags that can be used for multiple component analyses in biomedical and other fields.
Previously, the principle of fluorescent energy transfer (ET) was used to enhance fluorescence emission for the successful development of four ET
tags for deoxyribonucleic acid (DNA) sequencing which are widely used in the Human Genome Project (Ju et ai. 1995, 1996). Tags containing fluorophores in energy transfer relationships have been disclosed in U.S. Patent 6,028,190.
USES THEREOF
This application claims priority of Provisional Application no. 60/309,156, filed July 31, 2001 and is a continuation in part of U.S. Serial No.
09/658,077, filed September 11, 2000, the contents of both of which are hereby incorporated by reference into the subject application.
Throughout this application, various publications are referenced in parentheses by author and year. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
Background Of The Invention The need to study many biological targets simultaneously drives the development of multiplex fluorescent tags. However, due to the limits of the spectral region, and therefore the availability of appropriate detectors, the number of available fluorescent dyes that have distinguishable emission spectra is limited to about ten. To overcome this limitation, a combinatorial fluorescent labeling approach for multi-color fluorescence in situ hybridization (M-FISH) has been developed and is now widely used in the field of cytogenetics (Speicher et al., 1996; Schrock et ai., 1996). This approach mixes from two to seven individual fluorescent dyes that have unique emissions, and uses the fluorescence emission pattern to identify the different targets.
The unique fluorescence emission pattern is achieved by mathematically combining the different dyes. This development has made possible advances in chromosome analyses. However, the procedure requires physically mixing the individual dyes in a quantitative manner to develop "unique" probe labels. This requirement, coupled with the potential interactions of the dyes, complicates the fluorescence emission patterns.
Therefore, the major application of the technique is limited to methods that involve hybridization.
Multiple lasers and detectors are also required for the imaging. A reagent kit that can be used to covalently label a wide range of biomolecules is difficult to construct with this approach. Thus, there is an urgent need for a large set of fluorescent tags that can be used for multiple component analyses in biomedical and other fields.
Previously, the principle of fluorescent energy transfer (ET) was used to enhance fluorescence emission for the successful development of four ET
tags for deoxyribonucleic acid (DNA) sequencing which are widely used in the Human Genome Project (Ju et ai. 1995, 1996). Tags containing fluorophores in energy transfer relationships have been disclosed in U.S. Patent 6,028,190.
Summary Of The Invention This invention provides a composition of matter comprising multiple fluorophores, each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer between one such fluorophore and another such fluorophore, wherein the one such fluorophore and the another such fluorophore are characterized by the maximum emission wavelength of one being greater than the minimum excitation wavelength of the other.
This invention further provides the instant composition of matter comprising two fluorophores, each of which is bound to a molecular scaffold, at a separate predetermined position on the scaffold, such separate positions being selected so as to permit fluorescence energy transfer between such fluorophores, and such fluorophores being characterized by the maximum emission wavelength of one of the fluorophores being .greater than the minimum excitation wavelength of the other fluorophore.
This invention further provides the instant composition of matter comprising three fluorophores each of which is bound to a molecular scaffold at- a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer among such fluorophores and such fluorophores being characterized by the maximum emission wavelength of one such fluorophore being greater than the minimum excitation wavelength of the second such fluorophore and the maximum emission wavelength of such second fluorophore being greater than the minimum excitation wavelength of the third such fluorophore.
This invention further provides the instant composition of matter, wherein each fluorophore is covalently bound to the molecular scaffold.
This invention further provides the instant composition of matter, wherein the efficiency of the fluorescence energy transfer is less than 20%.
This invention further provides the instant composition of matter, wherein the molecular scaffold is rigid.
This invention further provides the instant composition of matter, wherein the molecular scaffold is polymeric.
This invention further provides the instant composition of matter, wherein the molecular scaffold comprises a nucleic acid.
This invention further provides the instant composition of matter, wherein the molecular scaffold comprises a peptide.
This invention further provides the instant composition of matter, wherein the molecular scaffold 5 comprises a polyphosphate.
This invention further provides the instant composition of matter, wherein at least one fluorophore is a fluorescent dye.
This invention further provides the instant composition of matter, wherein the fluorescent dye is 6-carboxyfluorescein.
This invention further provides the instant composition of matter, wherein the fluorescent dye is N,N,N',N'-tetramethyl-6-carboxyrhodamine.
This invention further provides the instant composition of matter, wherein the fluorescent dye is cyanine-5 monofunctional dye.
This invention further provides the instant composition of matter, wherein at least one fluorophore is a luminescent molecule.
This invention further provides the instant composition of matter, wherein at least one fluorophore is a quantum dot.
This invention also provides a composition of matter having the structure:
FAM TAM
SW T -~S~m T -R
wherein S represents G 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, each T represents a thymidine derivative, FAM represents 6-carboxyfluorescein derivative, TAM represents N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
This invention further provides the instant composition of matter, wherein m is 4.
This invention further provides the instant composition of matter, wherein m is 6.
This invention further provides the instant composition of matter, wherein m is G.
This invention further provides the instant composition of matter comprising two fluorophores, each of which is bound to a molecular scaffold, at a separate predetermined position on the scaffold, such separate positions being selected so as to permit fluorescence energy transfer between such fluorophores, and such fluorophores being characterized by the maximum emission wavelength of one of the fluorophores being .greater than the minimum excitation wavelength of the other fluorophore.
This invention further provides the instant composition of matter comprising three fluorophores each of which is bound to a molecular scaffold at- a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer among such fluorophores and such fluorophores being characterized by the maximum emission wavelength of one such fluorophore being greater than the minimum excitation wavelength of the second such fluorophore and the maximum emission wavelength of such second fluorophore being greater than the minimum excitation wavelength of the third such fluorophore.
This invention further provides the instant composition of matter, wherein each fluorophore is covalently bound to the molecular scaffold.
This invention further provides the instant composition of matter, wherein the efficiency of the fluorescence energy transfer is less than 20%.
This invention further provides the instant composition of matter, wherein the molecular scaffold is rigid.
This invention further provides the instant composition of matter, wherein the molecular scaffold is polymeric.
This invention further provides the instant composition of matter, wherein the molecular scaffold comprises a nucleic acid.
This invention further provides the instant composition of matter, wherein the molecular scaffold comprises a peptide.
This invention further provides the instant composition of matter, wherein the molecular scaffold 5 comprises a polyphosphate.
This invention further provides the instant composition of matter, wherein at least one fluorophore is a fluorescent dye.
This invention further provides the instant composition of matter, wherein the fluorescent dye is 6-carboxyfluorescein.
This invention further provides the instant composition of matter, wherein the fluorescent dye is N,N,N',N'-tetramethyl-6-carboxyrhodamine.
This invention further provides the instant composition of matter, wherein the fluorescent dye is cyanine-5 monofunctional dye.
This invention further provides the instant composition of matter, wherein at least one fluorophore is a luminescent molecule.
This invention further provides the instant composition of matter, wherein at least one fluorophore is a quantum dot.
This invention also provides a composition of matter having the structure:
FAM TAM
SW T -~S~m T -R
wherein S represents G 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, each T represents a thymidine derivative, FAM represents 6-carboxyfluorescein derivative, TAM represents N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
This invention further provides the instant composition of matter, wherein m is 4.
This invention further provides the instant composition of matter, wherein m is 6.
This invention further provides the instant composition of matter, wherein m is G.
This invention further provides the instant composition of matter, wherein m is 13.
This invention also provides a composition of matter having the structure:
FAM Cy5 Q- T - ~S)m T-R
wherein S represents G 1',2'-dideoxyribose phosphate moiety, m is an integer greater than l and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
This invention further provides the instant composition of matter, wherein m is 4.
Thi° invention further provides the instant composition of matter, wherein m is 5.
This invention also provides a composition of matter having the structure:
FAM Cy5 Q- T - ~S)m T-R
wherein S represents G 1',2'-dideoxyribose phosphate moiety, m is an integer greater than l and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
This invention further provides the instant composition of matter, wherein m is 4.
Thi° invention further provides the instant composition of matter, wherein m is 5.
This invention further provides the instant composition of matter, wherein m is 7.
This invention further provides the instant composition of matter, wherein m is 10.
This invention further provides the instant composition of matter, wherein m is 13.
This invention also provides a composition of matter comprising the structure shown below:
FAM TAM Cy5 Q_ T -(S)m T -- ~S)n-T_R
wherein S represents G 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, n is an integer greater than 1' and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, TAM represents a N,N,N',N'- etramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and ~~
are different.
This invention further provides the instant composition of matter, wherein m is 3, and n is 7.
This invention further provides the instant composition of matter, wherein m is 4, and n is 6.
2p This invention further provides the instant composition of matter, wherein m is 5, and n is 5 This invention further provides the instant composition of matter, wherein m is 6, and n is 6.
This invention further provides the instant composition of matter, wherein m is 7, and n is 7.
This invention also provides a composition of matter 20 comprising the structure shown below:
TA M TAM
Q_ T -(S)m T-R
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m represents an integer greater than 1 and less than 100, T represents a thymidine derivative, and TAM represents a 5 N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q
This invention further provides the instant composition of matter, wherein m is 10.
This invention further provides the instant composition of matter, wherein m is 13.
This invention also provides a composition of matter comprising the structure shown below:
FAM TAM Cy5 Q_ T -(S)m T -- ~S)n-T_R
wherein S represents G 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, n is an integer greater than 1' and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, TAM represents a N,N,N',N'- etramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and ~~
are different.
This invention further provides the instant composition of matter, wherein m is 3, and n is 7.
This invention further provides the instant composition of matter, wherein m is 4, and n is 6.
2p This invention further provides the instant composition of matter, wherein m is 5, and n is 5 This invention further provides the instant composition of matter, wherein m is 6, and n is 6.
This invention further provides the instant composition of matter, wherein m is 7, and n is 7.
This invention also provides a composition of matter 20 comprising the structure shown below:
TA M TAM
Q_ T -(S)m T-R
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m represents an integer greater than 1 and less than 100, T represents a thymidine derivative, and TAM represents a 5 N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q
10 are different.
This invention further provides the instant composition of matter, wherein m is 4.
This invention also. provides a nucleic acid labeled with any of the instant compositions.
This invention provides any of the instant compositions, wherein the nucleic acid is DNA.
This invention provides any of the instant compositions, wherein the nucleic acid is RNA.
This invention provides any of the instant compositions, wherein the nucleic acid is DNA/RNA.
This invention also provides a method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:
(a) contacting the nucleic acid, under hybridizing and DNA ligation-permitting conditions, with (i) a DNA ligase, (ii) a first oligonucleotide having affixed thereto a composition of matter of claim 1 wherein the first oligonucleotide hybridizes with nucleotides immediately adjacent one side of the predetermined position and (iii) a second oligonucleotide which hybridizes with the nucleotides immediately adjacent the other side of the predetermined position, wherein the hydroxy-terminal residue of the oligonucleotide which hybridizes to the nucleotide located 3' of the predetermined position is a nucleotide which is complementary to the preselected nucleotide residue; and (b) detecting the presence of a ligation product comprising both the first and the second oligonucleotides, the presence of such a ligation product indicating the presence of the preselected nucleotide z5 residue at the predetermined position.
This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected 30 nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.
This invention provides the instant method, wherein the presence of a plurality of given nucleotide residues is determined simultaneously.
This invention further provides the instant method, wherein the DNA ligase is Taq DNA ligase.
This invention further provides the instant method, wherein the second oligonucleotide has an isolation-permitting moiety affixed thereto, and wherein the method further comprises the steps of isolating the moiety-containing molecules resulting from step (a) and determining the presence therein of ligated first and second oligonucleotides.
This invention further provides the instant method, wherein the composition of matter affixed to the first oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of ligated first and second oligonucleotides in step (b).
This invention also provides a method of determining whether a. preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of: ' (a) contacting the nucleic acid, under hybridizing and DNA polymerization-permitting conditions, with (i) a DNA polymerase, (ii) an oligonucleotide (1) having affixed thereto a composition of matter of claim 1, and (2) having a hydroxyl 3' terminus thereof, wherein the oligonucleotide hybridizes with the 3' region of the nucleic acid molecule flanking the predetermined position, and (iii) a dideoxynucleotide labeled with an isolation permitting moiety, wherein the labeled dideoxynucleotide is complementary to the given nucleotide residue, with the proviso that upon hybridization of the oligonucleotide with the nucleic acid in the presence of DNA polymerase and the preselected nucleotide residue, the oligonucleotide and dideoxynucleotide are juxtaposed so as to permit their covalent linkage by the DNA polymerase;
(b) detecting the presence of a polymerization product comprising both the oligonucleotide and the dideoxynucleotide, the presence of such a polymerization product indicating the presence of the preselected nucleotide residue at the predetermined position.
This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.
This invention further provides the instant method, wherein the DNA polymerase is thermo sequenase.
This invention further provides the instant method, wherein the dideoxynucleotide is selected from the group consisting of dideoxyadenosine triphosphate, dideoxycytidine triphosphate, dideoxyguanosine triphosphate, dideoxythymidine triphosphate, and dideoxyuridine triphosphate.
This invention further provides the instant method, wherein the composition of matter affixed to the oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of polymerization product in step (b).
This invention further provides the instant methods, wherein observing the predetermined emission spectrum is performed using radiation having a wavelength of between 200 and 1000nm.
This invention further. provides the instant methods, wherein the radiation has a wavelength of 488 nm.
This invention further provides the instant methods, wherein observing the predetermined emission spectrum 5 is performed using radiation having a bandwidth of between 1 and 50nm.
This invention further provides the instant methods, wherein the radiation bandwidth is lnm.
This invention further provides the instant methods, wherein the isolation-permitting moiety comprises biotin, streptavidin, phenylboronic acid, salicylhydroxamic acid, an antibody or an antigen.
This invention further provides the instant methods, wherein the isolation-permitting moiety is attached to the oligonucleotide via a linker molecule.
This invention further provides the instant methods, wherein the isolation-permitting moiety is attached to the dideoxynucleotide via a linker molecule.
This invention further provides the instant methods, wherein the linker molecule is chemically cleavable.
This invention further provides the instant methods, wherein the linker molecule is photocleavable.
This invention further provides the instant methods, wherein the linker molecule has the structure:
H
~ N
I IO
O.
Brief Description Of The Figures Figure 1A-B: (A) Schematic of a multi-chromophore assembly connected to a linker. In general, 1 to n chromophores can be attached to the assembly with the chromophores separated by spacers as shown.
Chromophores can be, but not limited to, fluorescent dyes, quantum dots or luminescent molecules such as terbium chelate. A variety of spacers such as nucleotides, peptides, a polymer linker formed by 1', 2'-dideoxyribose phosphates or other chemical moieties can be used. The assembly label shown here is connected to a linker which can be designed as nucleic acids, proteins or cells, etc for multiplex biological assays. (B) The synthesis of F-4-T-6-C.
The numbers in F-4-T-6-C refer to the number of spacing nucleotides in the scaffold between dyes F
and T, and T and C. F = Fam; T - Tam; C = Cyanine 5 monofunctional dye.
Figure 2A-D: Spectroscopic data for tags F-4-T-6-C
and F-7-T-3-C.
(A) Two tags with different fluorescent signatures have been constructed by varying the spacing between the three dyes F, T, and C.
(B) Ultraviolet/visible (UV/vis) absorption spectrum of dye F-4-T-6-C.
(C) Fluorescence emission spectra of dye F-4-T-6-C.
(D) Fluorescence emission spectra of dye F-7-T-3-C.
F = Fam; T = Tam; C = Cy5.
Figure 3A-B: Schematic labeling approach to construct CFET-primers and CFET-dUTPs. The spacer between dyes is 1',2'-dideoxyribose phosphate (S) in (A) and proline (P) in (B). "m" and "n" refer to the number of molecules in the spacer. dUTP
deoxyuridine triphosphate.
Figure 4: The synthesis of CFET-dUTP. The CFET tag comprises three different fluorescent dyes: Fam, Tam and Cy5.
Figure 5: Structures of Aminoallyl (AA)-dUTP, Fam-proline, and N-Hydroxy succinimide (NHS) esters of TAM and CyS.
Figure 6: Synthetic schemes to prepare Fam-proline, Azido-proline and Cy5-phosphine. TMSCI -trimethylsilyl chloride.
Figure 7: The eight unique fluorescence signatures of CFET tags generated in a three-color CAE system. FAM
channel (520 -~- 20 nm, dotted line), TAM channel (585 ~ 20 nm, solid thin line), Cy5 channel (670 ~ 20 nm, solid thick line). The digital ratio denoting the fluorescence signature for each CFET tag from the three channels [dotted:thin:thick] is shown in the brackets. The fluorescence signatures in the electropherogram were obtained by excitation at 488 nm and electrokinetic injection of the eight CFET-labeled oligonucleotides into the three-color CAE
system.
Figure 8A-B: Schematic of using ligase chain reaction for determining the genotype at a locus containing a possible single-base mutation.
(A) Primer pairs are generated surrounding a base that can be mutated. The wild-type primer is labeled with one CFET tag (Tag 1) and the mutation-specific primer with another CFET tag (Tag 2) .
(B) Subsequent gel electrophoresis allows separation of ligated primer pairs and unincorporated primers. Different bands appear. on the gel depending on whether the template is wild-type or mutated.
Figure 9: Schematic of expected results from screening four potential mutation sites of Rb1 gene using eight unique CFET Tags and the ligase chain reaction assay. Only ligation products are shown on the gels.
Figure 10: Schematic of chromosomal studies to detect macrodeletions and amplifications.
Figure 11: This figure schematically shows the procedure for multiplex SNP detection through the ligation of hybridized CFET-labeled and biotinylated oligonucleotides. Taq DNA ligase seals the nick between the two hybridized oligonucleotides if the nucleotides at the ligating junction are correctly base-paired to the template (A to T; C to G). CFET-labeled, biotinylated ligation products are them isolated using streptavidin-coated magnetic beads.
After washing and releasing from the magnetic beads, the ligation products are electrokinetically injected into a three-color CAE system. Each CFET-labeled ligation product, which identifies a unique SNP, is unambiguously detected due to its distinct mobility 5 and fluorescence signature in the CAE
electropherogram.
Figure 12A-B: Electropherogram of CFET-labeled ligation products for SNPs identification on exon 20 10 of the RB1. (A) Detection of six nucleotide variations from synthetic DNA templates. FAM (T) and F-10-Cy5 (T) peaks are obtained from two different locations of the same template. F-9-T (C) and F-13-T
(T) peaks indicate mutations from the same locus of a 15 DNA template, while F-4-T-6-Cy5 (A) and F-7-T-7-Cy5 (C) peaks identify mutations from the same locus of another DNA template. (B) Detection of three homozygous genotypes (T, C and A) from a PCR product of RB1.
Figure 13: This figure is a schematic of single base primer extension for multiplex SNP detection by using dye-labeled primers and biotinylated dideoxynucleoside triphosphates (ddNTP-Biotin). DNA
template containing polymorphic sites is incubated with a dye-labeled primer, hybridizing the template adjacent to the polymorphic site, ddNTP-Biotin and thermo sequenase. At the end of reaction and purification the primer extension products are analyzed for fluorescence signatures.
Figure 14: Three unique fluorescence signatures generated from dye-labeled extension products. FAM
channel (light) and TAM channel (Dark). The fluorescence signatures in the electropherograms were obtained by excitation at 488nm and the single base extension of the dye-labeled primers. The digital ratio denoting the fluorescence signature for each from the two detection channels is shown in parentheses.
Figure 15A-C: The electropherograms of CFET-labeled primer extension products for multiplex SNPs identification on the mimic of exon 20 of the RB1.
FAM channel (Light line) and TAM channel (Dark line).
(A): Detection of two individual homozygous genotypes from a wild type template. FAM (T) and F-9-T (C) peaks were obtained from two different loci on the template. (B): Similar to (A) except a mutated template was used. (C): Simultaneous detection of three nucleotide variations. FAM (T) peak was obtained from a locus of the template where a homozygous genotype was found. F-9-T (C) and F-13-T
(T) peaks indicate the mutation R661W (heterozygote) from the same locus of a DNA template.
Figure 16: Schematic of a high throughput channel based, moiety-based purification system. Sample solutions can be pushed back and forth between the two plates through glass capillaries and the coated channels in the chip, the channels being coated with an appropriate chemical to bind the moiety tag on the samples, e.g. streptavidin coating in the case of biotinylated oligonucleotides. Where the moieties are attached by cleavable linkers, e.g. photocleavable linkers, the whole chip can be irradiated to cleave the samples after immobilization.
Detailed Description Of The Invention Definitions The following definitions are offered as an aid to understanding the invention:
CAE - Capillary Array Electrophoresis CFET - Combinatorial fluorescence energy transfer;
Cy 5 - Cyanine 5 monofunctional dye;
ddNTP - Dideoxynucleotide trisphosphate;
FAM - 6-carboxyfluorescein;
nm - nanometer RB1 - Retinoblastoma gene;
SNP - Single nucleotide polymorphism;
TAM - N,N,N',N'-tetramethyl-6-carboxy rhodamine.
As used herein, and unless stated otherwise, each of the following terms shall have the definition set forth below.
"Chemically cleavable" shall mean cleavable by any chemical means including but not limited to pH and temperature.
"DNA/RNA" shall mean a nucleic acid molecule comprising both deoxyribonucleotides and ribonucleotides.
"Emission spectrum" shall mean the amplitude and frequency of energy emitted from a composition of matter as a result of exciting radiation thereon.
"Flexible", when used to describe a molecular scaffold, shall mean that the distance between the centers of any pair of fluorophores covalently bound to the scaffold varies by more than 50%.
"Fluorescence energy transfer" shall mean the transfer of energy between two fluorophores via a dipole-dipole interaction.
"Fluorescent dye" shall mean an organic dye molecule capable of emitting fluorescent energy of wavelength between 200 and 1000nm when excited by an energy of shorter wavelength wherein the emitted energy results from a singlet to singlet transition. Examples are 6-carboxyfluorescein, N,N,N',N'-tetramethyl-6-carboxyrhodamine, and cyanine-5 monofunctional dye.
"Fluorophore" shall mean a molecule, such as a fluorescent dye, quantum dot or luminescent molecule, capable of emitting energy of wavelength between 400 and 1000nm when excited by an energy of shorter wavelength than the corresponding emission wavelength. Examples of fluorophores include 6-carboxyfluorescein, N,N,N',N'-tetramethyl-6-carboxy rhodamine, cyanine-5 monofunctional dye, zinc sulfide-capped cadmium selenide quantum dots, and lanthanide chelates.
"Hybridize" shall mean the annealing of one single-stranded nucleic acid molecule to another single stranded nucleic acid molecule based on sequence complementarity. The propensity for hybridization between nucleic acids depends on the temperature and ionic strength of their milieu, the length of the nucleic acids and the degree of complementarity. The effect of these parameters on hybridization is well 5 known in the art (see Sambrook, 1989).
"Isolation-permitting moieties" shall include without limitation biotin or streptavidin which bind to one another, antibodies or antigens which bind to one 10 another, phenylboronic acid or salicylhydroxamic acid which bind to one another.
"Ligation-permitting conditions" include without limitation conditions of temperature, ionic strength, 15 ionic composition, molecular composition, orientation and viscosity that allow one oligonucleotide to be joined enzymatically to another via a phosphodiester bond.
20 "Ligation" shall mean the enzymatic covalent joining of a nucleic acid with either another nucleic acid or a single nucleotide.
"Linker molecule" shall mean a chemical group used to 25 covalently join two other molecules. An example of a linker molecule is the structure given below:
H
N
"Luminescent molecule" shall mean a molecule capable of emitting energy of wavelength between 200 and 1000nm when excited by energy of shorter wavelength than the corresponding emission wavelength, wherein the emitted energy does not result from a singlet to singlet transition. Examples of luminescent molecules include europium polycarboxylate chelate and terbium chelates.
"Molecular scaffold" shall mean a molecular structure to which two or more fluorophores can be, and/or are, covalently bound at discrete loci thereon. Ideally, a molecular scaffold is polymeric, comprising monomeric units to which fluorophores can be bound. The monomeric units which make up such polymeric scaffold can, but need not be; identical. Examples of such monomeric units include 1',2'-dideoxyribose phosphate and thymidine.
"Nucleic acid molecule" shall mean any nucleic acid molecule, including, without limitation, DNA, RNA and hybrids thereof. The nucleic acid bases that form nucleic acid molecules can be the bases A, C, G, T
and U, as well as derivatives thereof. Derivatives of these bases are well known in the art, and are exemplified in PCR Systems, Reagents and Consumables (Perkin Elmer Catalogue 1996-1997, Roche Molecular Systems, Inc., Branchburg, New Jersey, USA).
"Oligonucleotide" shall mean a nucleic acid comprising two or more nucleotides.
"Photocleavable" shall mean cleavable by electromagnetic energy of between 200 and 1000nm wavelength.
"Polymeric" shall describe a molecule composed of more than two monomeric units.
"Quantum dot" shall mean a nanometer-sized composition of matter comprising a semi-conductor or metal, wherein such composition is capable of luminescence. Examples of quantum dots include zinc-sulfide-capped cadmium selenide quantum dots.
"Rigid", when used to describe a molecular scaffold, shall mean that the distance between the centers of any pair of fluorophores covalently bound to the scaffold does not vary more than 500.
Embodiments of the Invention This invention provides a composition of matter comprising multiple fluorophores, each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer between one such fluorophore and another such fluorophore, wherein the one such fluorophore and the another such fluorophore are characterized by the maximum emission wavelength of one being greater than the minimum excitation wavelength of the other.
This invention further provides the instant composition of matter comprising two fluorophores, each of which is bound to a molecular scaffold, at a separate predetermined position on the scaffold, such separate positions being selected so as to permit fluorescence energy transfer between sucn fluorophores, and such fluorophores being characterized by the maximum emission wavelength of one of the fluorophores being greater than the minimum excitation wavelength of the other fluorophore.
This invention further provides the instant composition of matter comprising three fluorophores each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer among such fluorophores and such fluorophores being characterized by the maximum emission wavelength of one such fluorophore being greater than the minimum excitation wavelength of the second such fluorophore and the maximum emission wavelength of such second fluorophore being greater than the minimum excitation wavelength of the third such fluorophore.
In one embodiment each fluorophore is covalently bound to the molecular scaffold.
In one embodiment the efficiency of the fluorescence energy transfer is less than 200.
In one embodiment the molecular scaffold is rigid.
In one embodiment the molecular scaffold is polymeric.
In one embodiment the molecular scaffold comprises a nucleic acid.
In one embodiment the molecular scaffold comprises a peptide.
In one embodiment the molecular scaffold comprises a polyphosphate.
In one embodiment at least one fluorophore is a fluorescent dye.
In one embodiment the fluorescent dye is 6-carboxyfluorescein.
In one embodiment the fluorescent dye is N,N,N',N'-tetramethyl-6-carboxyrhodamine.
In one embodiment the fluorescent dye is cyanine-5 monofunctional dye.
In one embodiment at least one fluorophore is a luminescent molecule.
In one embodiment at least one fluorophore is a quantum dot.
This invention also provides a composition of matter having the structure:
FAM TAM
Q- T -(S)m T -R
wherein S represents a 1',2'-dideoxyribose 10 phosphate moiety, m is an integer greater than 1 and less than 100, each T represents a thymidine derivative, FAM represents 6-carboxyfluorescein derivative, TAM represents N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line 15 represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
20 In one embodiment m is 4. In one embodiment m is 6.
In one embodiment m is 9. In one embodiment m is 13.
This invention also provides a composition of matter having the structure:
FAM Cy5 Q_ T - ~S)mrT_R
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
In one embodiment m is 4. In one embodiment m is 5.
In one embodiment n m is 7. In one embodiment m is 10. In one embodiment m is 13.
This invention. also provides a composition of matter comprising the structure shown below:
FAM TAM Cy5 Q T WS)rWT -~S)n-T-R
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, n is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that~R and Q
are different.
In one embodiment m is 3, and n is 7. In one embodiment, wherein m is 4, and n is 6. In one embodiment m is 5, and n is 5. In one embodiment m is 6, and n is 6. In one embodiment m is 7, and n is 7.
This invention also provides a composition of matter comprising the structure shown below:
TAM TAM
Q_ T -(S)m T-R
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m represents an integer greater than 1 and less than 100, T represents a thymidine derivative, and TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q
are different.
In one embodiment m is 4.
This invention also provides a nucleic acid labeled with any of the instant compositions.
In one embodiment the nucleic acid is DNA.
In one embodiment the nucleic acid is RNA.
In one embodiment the nucleic acid is DNA/RNA.
This invention also provides a method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:
(a) contacting the nucleic acid, under hybridizing and DNA ligation-permitting conditions, with (i) a DNA ligase, (ii) a first oligonucleotide having affixed thereto a composition of matter of claim 1 wherein the first oligonucleotide hybridizes with nucleotides immediately adjacent one side of the predetermined position and (iii) a second oligonucleotide which hybridizes with the nucleotides immediately adjacent the other side of the predetermined position, wherein the hydroxy-terminal residue of the oligonucleotide which hybridizes to the nucleotide located 3' of the predetermined position is a nucleotide which is complementary to the preselected nucleotide residue; and (b) detecting the presence of a ligation product comprising both the first and the second oligonucleotides, the presence of such a ligation product indicating the presence of the preselected nucleotide residue at the predetermined position.
This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.
In one embodiment the presence of a plurality of given nucleotide residues is determined simultaneously.
In one embodiment the DNA ligase is Taq DNA ligase.
This invention further provides the instant method, wherein the second oligonucleotide has an isolation-permitting moiety affixed thereto, and wherein the method further comprises the steps of isolating the moiety-containing molecules resulting from step (a) and determining the presence therein of ligated first and second oligonucleotides.
This invention further provides the instant method, wherein the composition of matter affixed to the first oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of ligated first and second oligonucleotides in step (b) .
This invention also provides a method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:
5 (a) contacting the nucleic acid, under hybridizing and DNA polymerization-permitting conditions, with (i) a DNA polymerase, (ii) an oligonucleotide (1) having affixed thereto a composition of matter of claim l, and (2) having 10 a hydroxyl 3' terminus thereof, wherein the oligonucleotide hybridizes with the 3' region of the nucleic acid molecule flanking the predetermined position, and (iii) a dideoxynucleotide labeled with an isolation-15 permitting moiety, wherein the labeled dideoxynucleotide is complementary to the given nucleotide residue, with the proviso that upon hybridization of the oligonucleotide with the nucleic acid in the 20 presence of DNA polymerase and the preselected nucleotide residue, the oligonucleotide and dideoxynucleotide are juxtaposed so as to permit their covalent linkage by the DNA polymerase;
(b) detecting the presence of a polymerization 25 product comprising both the oligonucleotide and the dideoxynucleotide, the presence of such a polymerization product indicating the presence of the preselected nucleotide residue at the predetermined position.
This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.
In one embodiment the DNA polymerase is thermo sequenase.
This invention further provides the instant method, wherein the dideoxynucleotide is selected from the group consisting of dideoxyadenosine triphosphate, dideoxycytidine triphosphate, dideoxyguanosine triphosphate, dideoxythymidine triphosphate, and dideoxyuridine triphosphate.
This invention further provides the instant method, wherein the composition of matter affixed to the oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of polymerization product in step (b).
This invention further provides the instant methods, wherein observing the predetermined emission spectrum is performed using radiation having a wavelength of between 200 and 1000nm.
In one embodiment the radiation has a wavelength of 488 nm.
This invention further provides the instant methods, wherein observing the predetermined emission spectrum is performed using radiation having a bandwidth of between 1 and 50nm.
In one embodiment the radiation bandwidth is lnm.
This invention further provides the instant methods, wherein the isolation-permitting moiety comprises biotin, streptavidin, phenylboronic acid, salicylhydroxamic acid, an antibody or an antigen.
This invention further provides the instant methods, wherein the isolation-permitting moiety is attached to the oligonucleotide via a linker molecule.
This invention further provides the instant methods, wherein the isolation-permitting moiety is attached to the dideoxynucleotide via a linker molecule.
This invention further provides the instant methods, wherein the linker molecule is chemically cleavable.
This invention further provides the instant methods, wherein the linker molecule is photocleavable.
This invention further provides the instant methods, wherein the linker molecule has the structure:
~ N
I'O
O;
This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.
Experimental Details I. The Design of Combinatorial Fluorescence Energy Transfer Tags Background: Optical interactions persist between two chromophores even when they are as far as 80 angstroms apart. The chromophore with high energy absorption is defined as a donor, and the chromophore with lower energy absorption is defined as an acceptor. Fluorescence energy transfer is mediated by a dipole-dipole coupling between the chromophores that results in resonance transfer of excitation energy from an excited donor molecule to an acceptor (Forster, 1965). Forster established that the energy transfer efficiency is proportional to the inverse of the sixth power of the distance between the two chromophores. Fluorescence resonance energy transfer has been used extensively as a spectroscopic ruler for biological structures (Stryer, 1978), and energy transfer-coupled tandem phycobiliprotein conjugates have found wide applications as unique fluorescent labels (Glazer and Stryer, 1983). A set of polycationic heterodimeric fluorophores that exploit energy transfer and have high affinities for double-stranded DNA were also developed, offering advantages over monomeric fluorophores in multiplex fluorescence labeling applications (Benson et al., 1993; Rye et al., 1993). By exploiting fluorescence energy transfer principle, using a common donor and four different acceptors, tour sets of ET primers and dideoxynucleotides were constructed that are markedly superior to single dye labels in DNA sequencing, and in multiplex polymerase chain reaction (PCR)-based mapping and sizing protocols (Ju et al., 1995, 1996).
The present application discloses how energy transfer 5 and combinatorial concepts can be used to tune the fluorescence emission signature of fluorescent tags for the development of a large number of combinatorial fluorescence energy transfer (CFET) tags. A schematic construction of the tags is shown 10 in Figure 1a. Representative examples for the construction of the CFET tags and their expected fluorescence signatures are shown in Table 1. Three individual fluorescent dyes, 6-carboxyfluorescein (FAM or F), N,N,N',N'-tetramethyl-6-carboxyrhodamine 15 (TAM or T) and Cyanine dye (Cy5 or C) are selected as examples to construct the CFET tags. The fluorescence emission maxima for FAM, TAM and Cy5 are 525nm, 580nm and 670nm, respectively. Chemical moieties used as spacers are selected to construct 20 various CFET tags aimed at conveniently labeling biomolecules and other targets of interest, monomers are convenient to employ. Other spacer moieties include nucleotides, peptides and 1'2'-dideoxyribose phosphates. As shown in Table 1, tag 1 is constructed 25 with FAM alone and displays its characteristic fluorescence signature (?Amax - 525 nm). Any fluorophore with a characteristic fluorescence signature could be used in place of FAM. With FAM as a donor and TAM as an acceptor, CFET tags 2, 3, 4, 30 and 5 can be constructed by changing the distance "R"
between the FAM and TAM chromophores. The rationale is that altering the distance between donor and acceptor changes the energy transfer efficiency, and therefore the ratio of the fluorescence emission intensity of the donor (FAM) and acceptor (TAM).
Similarly, with FAM as a donor and Cy5 as an acceptor, CFET tags 6, 7 and 8 can be generated.
With three dyes, with FAM as a donor, TAM as an acceptor for FAM and as a donor for Table 1 Representative Example of CFET Tags CFET Tag Fluorescence Tag ID
Signature F 525 nm R ' 525 nm 580 nm ' F
~
r~~
R
T
525 nm 580 nm F~ R T
525 nm 580 nm R~
F T
525 nm 580 nm 525 nm 670 nm r i F C 525 nm 670 nm F G
525 nm 670 nm F R' T ~ C
525 nm 580 nm 670 nm FTC . 10 525 nm 580 nm 670 nm Cy5, which acts as the final acceptor, CFET tags 9 and 10 can be constructed by manipulating distances "R1" and "R2". All the CFET tags can be excited with a single laser source and analyzed by simple detectors capable of capturing the emission signatures from each tag. In other embodiments, more than three dyes can be used. Alternatively just single chromophores can be used as long as they have unique fluorescence signatures.
The donor and acceptor fluorescent molecules are separated using convenient chemical moieties as spacers to tune the fluorescence signatures of the CFET tags. Examples of such spacer moieties include nucleotides, dideoxyribose phosphate, and amino acids. The construction of CFET tags involving three or more different dyes is more challenging, since synthetic procedures need to be designed for introducing the individual dye molecules at specific locations on the spacing backbone. As an example, CFET tags involving three dyes can be constructed using oligonucleotides as spacers. An oligonucleotide with the sequence 5'-TTTTTTTTTTTTTTTTTTTTTTTTTC-3' (SEQ ID NO: 1) was selected as a scaffold to covalently attach FAM, TAM and CyS. FAM is introduced by using a 6-FAM-dT phosphoramidite, TAM
is introduced by using TAM-dT (Glen Research, Sterling, VA), and a modified T having an amino linker at the C-5 position (Glen Research) is incorporated into the oligonucleotide which is then linked to Cy5 - N-Hydroxy succinimide (NHS) ester.
The final product is purified by size exclusion chromatography and gel electrophoresis. A
representative reaction for the construction of CFET
tag F-4-T-6-C (the numbers refer to the number of spacing nucleotides) involving FAM, TAM and Cy5 is shown in Figure 1. By changing the spacing between FAM and TAM, and TAM and Cy5, two CFET tags F-4-T-6-C
and F-7-T-3-C with the fluorescence signatures corresponding to tags 9 and 10 have been constructed as shown in Figure 2. Shown are the ultraviolet/visible absorption spectrum of F-4-T-6-C
(Figure 2B) as well as the fluorescence emission spectra for F-4-T-6-C and F-7-T-3-C (Figures 2C and 2D), with excitation at 488 nm (1x Tris-Borate-Ethylenediaminetetraacetic acid (TBE) solution). The UV/visible spectrum exhibits the characteristic absorption of FAM at 495 nm, TAM at 555 nm and Cy5 at 649 nm (Figure 2B). The fluorescence emission spectrum of F-4-T-6-C displays a fluorescence signature with Cy5 highest, TAM next and FAM lowest;
whereas F-7-T-3-C displays a fluorescence signature with FAM highest, TAM next and Cy5 lowest. The two fluorescence signatures are clearly different, and easily discernible by spectroscopic methods. Here the feasibility of the CFET approach involving three different dyes is clearly demonstrated.
It is evident that one can synthesize broad families of CFET tags. Examples of two synthetic approaches for constructing CFET tags are shown: (1) 1',2'-dideoxyribose phosphate monomer can be used as a spacer to separate dyes used for labeling oligonucleotide primers, which can be assembled on a DNA synthesizer; (2) a rigid peptide linker can be used to construct a CFET cassette to label any other molecular targets.
The first example is shown in Figure 3A. A polymer 5 linker (SSS...SSSS) formed by 1' , 2' -dideoxyribose phosphates (S) at the 5' end of the desired primer sequence forms a universal spacer for attaching the ET-coupled fluorophores, thereby producing an ET
cassette. The 1',2'-dideoxyribose phosphates can be 10 introduced using 5'-dimethoxytrityl-1',2'-dideoxyribose-3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (dSpacer CE Phosphoramidite, Glen Research, Sterling, VA). dSpacer CE Phosphoramidite has previously been used to construct DNA sequencing 15 primers (Ju et al., 1996). In this CFET tag construction, FAM is used as a common donor. In a CFET tag consisting of two different fluorescent dyes, either TAM or Cy5 can be used as acceptors;
whereas in a CFET tag consisting of three different 20 fluorescent dyes, TAM can also be used as a donor for Cy5. The length of the spacing between each donorlacceptor pair can be changed systematically to achieve the expected fluorescence signatures as shown in Table 1. FAM and TAM can be introduced using 25 phosphoramidite FAM-dT and TAM-dT and Cy5 can be introduced to the modified T carrying an amino linker as described above. The use of such spacers is advantageous in several aspects: (i) the spacer will not hybridize to any sequences within the DNA
30 template and therefore false priming is avoided; (ii) the linkage of the spacer maintains the natural nucleic acid phosphate functionality, which avoids possible anomalies in electrophoretic mobility; and (iii) the elimination of the aromatic base groups on the deoxyribose rings in the spacer may reduce the likelihood of fluorescence quenching.
The second synthetic approach requires sophisticated selective synthetic chemistry procedures for the CFET
tag construction. As an example, Figure 3B shows a general scheme for the construction of CFET-deoxyuridine triphosphate (dUTP) using poly-proline (P) peptide as a spacer. The spacing between each donor/acceptor pair can be changed systematically to achieve the expected fluorescence signatures as shown in Table 1. Figure 4 shows a scheme for the synthesis of CFET-dUTP consisting of Fam, Tam and Cy5. Peptide synthesis procedure using tert-butylcarbonyl (t-Boc) chemistry is employed on a peptide synthesizer to construct the scaffold of the desired molecules. Starting with a glycine-resin as C-terminal, a modified proline tagged with FAM (Fam-proline) is coupled to glycine, then proline monomers are added, followed by reacting with another modified proline that has a protected primary amino linker (TFA-NH-proline) for the subsequent incorporation of Tam. Next, proline spacer is again added, followed by reacting with the azido-proline for the subsequent incorporation of CyS. After cleavage from the resin and removal of the trifluoroacetyl group, compound 1 in Figure 4 is obtained. Compound 1 reacts with TAM-NHS ester to form compound 2, which will then react with Cy5-phosphine (3) to produce compound 4, which has all the three dyes incorporated. Cy5-phosphine (3) can be synthesized using the modified Staudinger reaction developed by Bertozzi (Saxon and Bertozzi, 2000). Conversion of compound 4 to an NHS ester produces 5, which is then coupled to Aminoallyl (AA)-dUTP (Sigma) to generate the final product CFET-dUTP.
By varying the number of proline spacers between Fam and Tam, and between Tam and Cy5, a library of CFET-dUTPs with unique fluorescence signatures can be developed. The intermediates 2, 4, 5, and the final products can be purified by high pressure liquid chromatography (HPLC), size exclusion chromatography and gel electrophoresis.. The structures of AA-dUTP, Fam-Proline, and NHS esters of TAM and Cy5 are shown in Figure 5. Brief synthetic schemes for the synthesis of trifluoroacetic (TFA) - NH-proline, Fam-proline, azido-proline and Cy5-phosphine are shown in Figure 6. Unique fluorescence signatures for 8 synthesized CFET tags are shown in Figure 7.
II. Biomedical Applications of Combsnatora.al Fluorescence Energy Transfer Tags The ability to sequence DNA accurately and rapidly is revolutionizing biology and medicine. The confluence of the massive Human Genome Project is driving an exponential growth in the development of high throughput genetic analysis technologies. This rapid technological development involving biology, chemistry, computer science, and engineering makes it possible to move from studying genes one by one to approaches which can analyze and compare entire genomes.
Sophisticated techniques have enabled large-scale dissection of genomes. For instance, the development of cloning vectors which can maintain and reproduce large stretches of DNA (up to a million bases) has resulted in clone libraries which span most of the chromosomes from end to end for many of the highly S studied organisms including humans - so-called physical maps. Recognizing sequence markers that differ from one individual to another across the human genome has permitted them to be followed in families that harbor genetic diseases. If a marker cosegregates with the disease phenotype, one can be assured that the marker is in the vicinity of the gene responsible for that disease. Automated sequencing methods have made it possible to obtain the complete chemical composition of the genome with unprecedented speed, and computational approaches axe beginning to allow annotation of these sequences, identification of the genes and other elements that comprise the chromosomes. Gene expression has moved from the arena of analyzing a few genes at a time by the techniques of Northern blot analysis, to creating vast microarrays of these genes on glass slides or silicon chips (Schena et al. 1995, Chee et al. 1996).
Methods for identifying single nucleotide polymorphisms (SNPs) (Chen and Kwok, 1997), DNA-protein and protein-protein interactions (Uetz et al.
2000), and members of metabolic, signal transduction and other pathways are also being developed. All these advances will have the potential to revolutionize medical and clinical research in establishing diagnostic, prognostic or treatment options.
It is noteworthy that many of the genomic techniques mentioned have benefited from the use of novel molecular tags, especially fluorescent dye molecules.
DNA sequencing serves as a good example for evaluating the impact of this technology. Although the ability to obtain DNA sequences originated in the late 1970's with the development of the chemical cleavage approach of Maxam and Gilbert (1977) and the dideoxynucleotide terminator approach of Sanger et al . ( 1977 ) , it was the latter that was most amenable to automation and fluorescent labeling strategies.
In the past 15 years, in rapid succession, the ability to use four dyes in a single sequencing lane, one for each of the four bases in DNA (Smith et al.
1986), the ability to use cycle sequencing with heat stable enzymes (Tabor et al. 1995), the development of energy transfer dyes which produced higher signals (Ju et al., 1995; Lee et al., 1997), and mare recently, the ability to obtain long sequence reads in separate capillary tubes instead of adjacent lanes on polyacrylamide slab gels, has made sequencing increasingly robust. Future improvements in sequencing technology, including miniaturization and solid phase approaches, will continue to take advantage of energy transfer (ET) and other novel fluorescent tags (Ju et al., 1997). Investigators are also utilizing ET dyes for investigating gene expression on microarrays (Hacia et al. 1998). All of these approaches are believed to be limited to single pairs of donor and acceptor dyes for each reaction. The CFET approach described herein whereby one, two or more dyes, disposed at varying molecular distances from each other to generate many alternative discrete signatures offers the possibility of obtaining an order of magnitude higher throughput in many of these genomic approaches.
Genetic mutation and chromosome analysis are two 5 examples of the biomedical application of these CFET
tags. Using CFET tags in combination with single fluorophore tags, and/or multiple dye tags where no FET occurs, the number of possible unique fluorescence signatures, and hence the number of e.g.
10 SNPs detectable simultaneously, is hugely increased.
Gene mutations play important roles in the development of many human diseases. It has become increasingly apparent that missense mutations (single 15 base changes usually culminating in amino acid changes or introduction of stop codons which lead to truncated proteins), microdeletions and microinsertions (both of which can change the reading frame and also usually lead to protein truncation) 20 can occur at many positions along the length of the responsible gene. A number of studies have sought to identify causative mutations and predisposing polymorphisms for a number of cancers and other diseases. These include chronic lymphocytic leukemia 25 and other blood cancers (Kalachikov et al. 1997; Qu et al. 1998), the long QT syndrome (an ionic disturbance in the heart visible on electrocardiograms and an important risk factor for sudden cardiac death), breast cancer (Fischer et al.
30 1996), the rare ICF syndrome (immune deficiency/centromeric instabilitylfacial anomalies) (Xu et al. 1999), and more recently such complex disorders such as asthma and diabetes.
With the exception of the types of small mutations described above and single nucleotide polymorphisms that occur, on average, every 1000 nucleotides, the 6 billion nucleotide pairs that make up the diploid human genome are largely identical from individual to individual. Nonetheless, large deletions, amplifications and rearrangements do occur, and such chromosomal anomalies are often associated with serious and life-threatening diseases. The best known example is probably the third copy of chromosome 21 in individuals with Down syndrome, bu many other chromosomal translocations and macrodeletions are associated with cancer and other disease syndromes. If one is able to mark the positions along chromosomes with identifiable "color-coded" probes, it should be possible to easily detect such large-scale changes in chromosomal geography.
In fact, the field of chromosome painting (multicolor fluorescence in situ hybridization (M-FISH) has been used for just such analyses (Speicher et al. 1996). A
larger set of more readily separable CFET tag signatures might greatly aid in this enterprise. The established chromosome painting techniques require appropriate mixing of the different dyes prior to labeling, and so are used almost exclusively for labeling whole chromosomes.
III. CFET Tags for Multiplex Gene Mutation Detection Using I~igase Chain Reaction Ligase chain reaction (ZCR) is a procedure for genetic mutation analysis using ligase and a pair of oligonucleotides (Eggerding, 1995; Wu and Wallace, 1989; Landegren et al., 1988). Briefly, it is based on the fact that two adjacent oligonucleotides can only be ligated if the adjoining bases are complementary to the template strand. If there is a single base difference within two bases of the join site, ligation will not occur. Pairs of oligonucleotides are designed spanning the ligation site on the template DNA, including one harboring either the wild-type or mutated base. In the usual procedure, one of the oligonucleotides is radiolabeled at the phosphate group at its 5' end.
Following the ligase chain reaction, which involves multiple rounds of denaturing, primer annealing and ligation, one can separate the products from the substrates on polyacrylamide gels. The procedure can be modified using single stranded DNA template as shown in Figure 8 for testing using the CFET tags.
Primer pairs are generated surrounding a base that can be mutated. For example, the template may contain a T wild-type, wt) or C (mutated, mut) at the relevant position. The wt primers are complementary to the wt template at every position.
The primer on the right side of Figure 8A is labeled with CFET tag 1 to yield a specific fluorescent signature.. The mutation-specific primer, two bases longer than its wild-type analog, is complementary to every position of the mutated template. This primer is labeled with CFET tag 2 displaying another unique fluorescent signature. A common 20 base pair primer will be used on the other side of the ligation site .
In cases where ligation does not occur, because a wild-type oligonucleotide was used with a mutated template sequence, or a mutated oligonucleotide was used with a wild-type template sequence, the only fluorescent band on the acrylamide gel will be the size of the tagged primer. In contrast, if there is no mismatch at the ligation junction, two fluorescent bands, one the size of the primer and one the size of the joined primers will form. Following ligase chain reaction, the left and right primer will be ligated only if they are completely complementary to the 1p template. Thus, with a wt template, only a 40 base product will result, and only a 42 base product will result from a mut template as shown in Figure 8B. By virtue of the unique fluorescence emission signatures of the CFET tags, it is possible to display the products of several mutation positions simultaneously, each labeled with a different CFET
Tag. The ligated products can be separated and analyzed in a single gel lane. In order to accomplish this, the multiplex set of oligonucleotides that contain the potentially mutated position can be 5'-end labeled, each with a specific CFET tag. For example, one can test four different mutation sites using eight distinct CFET tags.
As shown in Table 2, eight primers labeled with eight unique CFET tags (1, 2, 3, 4, 5, 6, 9, and 10 of Table 1) can be constructed as shown in the general labeling scheme in Figure 3A using 1',2'-dideoxysugar phosphate (S) as spacers. For this set of CFET tag constructs, FAM is used as a common donor, and TAM
and/or Cy5 as acceptors. The length of the spacing between each donor/acceptor pair, (S)m and (S)n, can be changed systematically to achieve the expected fluorescence signatures as depicted in Table 1. FAM
and TAM can be introduced using FAM-dT and TAM-dT
phosphoramidites and Cy5 can be introduced to the modified T carrying an amino linker as described above.
The system can be tested, for example, by synthesizing single stranded DNA templates mimicking known single base mutations in exon 20 of the retinoblastoma susceptibility (RB1) gene (Schubert et al. 1994, Lohmann 1999). The sequences of two sets of synthetic templates (wt and mut) which can be used in the analysis are shown in Table 3. The sequence of the potential mutation positions is shown in bold-face as "A', "C", "G" and "T". Primer sets 1 and 2 in Table 2 are used for the testing of both wild type and mutated base positions of Template A, respectively while primer sets 3 and 4 are for testing both wild type and mutated base positions of Template B, respectively. To maximize the number of samples that can be detected on a polyacrylamide gel, the primers surrounding each "mutated" position can be designed to be a unique length as shown in Figure 9. For example, the two CFET labeled oligonucleotides (one for the wild-type gene and one for the mutated gene) surrounding mutation position 1 are 20 and 22 bases long, respectively, and the unlabeled common primer is 20 bases long. Any resulting ligation product will be either 40 or 42 bases long.
Likewise, for mutation position 2, 24 and 26 base labeled oligonucleotides can be constructed, as well as a different 20 base common primer, leading to ligation products of either 44 or 46 bases. More primers can, of course, be generated by making the sizing increment one base instead of two bases for each different mutation, or creating a second set of labeled primers whose ligation products run between 5 80 and 98 base pairs, between 120 and 138 base pairs, etc. Since single base pair resolution up to the length of ~ 400 by DNA fragments is easily achieved in polyacrylamide gel electrophoresis, the ligated products can be readily resolved in such standard 10 fluorescent gel systems. Furthermore, the advantage of being able to clearly distinguish the products based on their fluorescent signatures, as well as size, makes this assay extremely powerful. Expected gel electrophoresis results for this multiplex 15 testing system are shown on the right side of Figure 9. Here, template collection 1 is seen to contain only wt sequences. In contrast, template pool 2 contains one template with a mutation at position 2 and a heterozygote genotype at position 4.
Table 2. Eight primers used for multiplex mutation rlci-cri-i nn Primer 1L: 3'-ttaaaaagaataagggtgtc-5' (SEQ ID N0: 2) Primer 1R wt: 3'-Acatagccgatcggatagag-5'-CFET1 (SEQ ID N0: 3) Primer 1R mut: 3'-Tcatagccgatcggatagaggc-5'-CFET2 (SEQ ID N0: 4) Primer 2L: 3'-acatagccgatcggatagag-5' (SEQ ID NO: 5) Primer 2R wt: 3'-Gccgatttatgtgaaacacttgcg-5'-CFET3 ( SEQ I D NO : 6 ) Primer 2R mut: 3'-Accgatttatgtgaaacacttgcgga-5'-CFET4 (SEQ ID N0: 7) Primer 3L: 3'-cggaagacagactcgtgggt-5' (SEQ ID N0: 8) Primer 3R wt: 3'-Cttaatcttgtatagtagacctgggaaa-5'-CFET5 (SEQ ID N0: 9) Primer 3R mut: 3'-Attaatcttgtatagtagacctgggaaaag-5'-CFET6 (SEQ ID N0: 10) Primer 4L: 3'-atagtagacctgggaaaagg-5' (SEQ ID NO: 11) Primer 4R wt: 3''-Tcgtgtgggacgtcttactcatacttgagt-5'-CFET9 (SEQ ID NO: 12) Primer 4R mut: 3'-Gcgtgtgggacgtcttactcatacttgagtac-5'CFET10 (SEQ ID N0: 13) Table 3. The sequence of the two sets of synthetic templates (wt and mut) Template A:
5'-gtaaaaatgactaatttttcttattcccacagTgtatcggctagcctatc tcCggctaaatacactttgtgaacgccttctgtctgagcacccagaatta-3' (wild type) (SEQ ID N0: 14) 5'-gtaaaaatgactaatttttcttattcccacagAgtatcggctagcctatc tcTggctaaatacactttgtgaacgccttctgtctgagcacccagaatta-3' (mutated) (SEQ ID NO: 15) Tem late B:
5'-tacactttgtgaacgccttctgtctgagcacccaGaattagaacatatca tctggacccttttccAgcacaccctgcagaatgagtatgaactcatgaga-3' (wild type) (SEQ ID NO: 16) 5'-tacactttgtgaacgccttctgtctgagcacccaTaattagaacatatca tctggacccttttccCgcacaccctgcagaatgagtatgaactcatgaga-3' (mutated) (SEQ ID NO: 17) IV. CfET Tag Labeled Probes for Chromosome-wide Analysis Probes can be generated using a random primed labeling method to incorporate CFET-dUTP into chromosome-specific DNA molecules or cosmids disposed along the length of a given chromosome. Metaphase spreads of fresh cells or deparaffinized material can be prepared by standard methodologies, and the tagged probes can be hybridized to the chromosomes. Bulky ET dyes consisting of two individual fluorescent molecules, as well as dyes with a long linker, have been attached to deoxynucleotides (dNTPs) and dideoxynucleotides (ddNTPs) which have been shown to be good substrates for DNA polymerase (Rosenblum et al. 1997, Zhu et al. 1994). Thus, the CFET-dUTP
should be able to be incorporated into the growing strand by the polymerase reaction. In the actual random priming reaction, the ratio of regular deoxythymine triphosphate (dTTP) and CFET-dUTP can be adjusted, so that only a small portion of CFET-dUTP
will be incorporated into the growing chain, just enough to be detected by the optical method.
Numerical and structural chromosome rearrangements are a major cause of human mortality and, morbidity.
Aneuploidy of whole chromosomes accounts for at least 500 of early embryonic lethality, and also leads to severe patterns of congenital malformation such as Down syndrome. Segmental aneuploidies due to deletions and duplications also lead to malformation syndromes, as well as being associated with many types of cancer.
Traditional cytogenetic analysis is hampered by problems of resolution and interpretation inherent in standard banding analysis. In the last decade the use of fluorescent labeled DNA probes on chromosome preparations as well as on interphase nuclei has greatly improved the resolution and accuracy of cytogenetic diagnosis. Microdeletions and amplifications too small to be visible under the light microscope by banding can now be visualized using chromosome and region specific fluorescently labeled probes. Multiplexing this system is possible using combinations of probes labeled with different fluors. Sets of up to five differently labeled probes have been used for diagnostic purposes on interphase nuclei to determine aneuploidy in prenatal samples (Munne et al. 1998). M-FISH and Spectral Karyotyping use a combinatorial approach of five dyes to "paint"
all 23 pairs of human chromosomes so they can be distinguished using computerized image software (Schrock et al. 1996, Speicher et al. 1996).
However, these established techniques require careful mixing of dyes in controlled ratios. Quality control is often a problem, and the commercially available probes are very expensive.
CFET Tags are expected to have a substantial advantage over currently available dye sets. It should be possible to generate a larger number of CFET tag sets, reducing the need for a combinatorial approach. Quality control is also likely to be easier, since each probe needs to be labeled with only one tag, and probe sets can be mixed in equal quantities to produce multicolor FISH reagents.
5 CFET Tags for example could be used both for the detection of aneuploidy in interphase nuclei, and for the detection of submicroscopic chromosomal deletions and amplifications. For aneuploidy detection, for example, a set of eight different CFET tag labeled 10 probes can be prepared, each specific for one of the chromosomes most commonly involved in aneuploidy in either embryonic losses or birth defects (chromosomes 13, 15, 16, 18, 21, 22, X and Y) .
15 A schematic of a procedure for comprehensive chromosome-wide analysis for gain or loss of genetic material is shown in Figure 10. In the example, eight probes each labeled with a CFET-dUTP that emits a unique fluorescence signature are hybridized along 20 a chromosome in eight separate locations. The normal chromosome A will display eight unique fluorescence signatures of each probe in a defined order. A loss of fluorescence signature "2" in chromosome B will indicate the deletion of the complementary sequence 25 of probe 2. Whereas, in chromosome C, the appearance of two signatures of "3" will indicate the expansion of the complementary sequences for probe 3.
Standard sets of cosmid and BisAcryloylCystamine 30 (BAC) markers at 2-3 Mb intervals along the chromosomes are being developed in several laboratories, including a National Cancer Institute sponsored project, the Cancer Chromosome Aberration Project (CCAP: webpage ::~.,~~: . ncbi . nlm. nih . ~oTa/nci~.::~,ao,r j . Sets of differentially CFET-labeled ordered probes specific for particular chromosomal regions can be prepared.
Using FISH, one can then determine the limits of suspected or known deletions.
V. Use of CFET Tags In Other Multi-Component Analyses The CFET tags with unique fluorescence signatures which are disclosed in the present application will have utility in other applications involving multi component analysis in addition to those disclosed above. Additional applications include, but are not limited to, multiplex assays including binding assays and immuno assays, detection of microbial pathogens, monitoring multiple biomolecular reactions, screening of drugs or compounds, epitope mapping, allergy screening, and use with organic compounds and in material science. For example, multiple reactions or interactions can be measured simultaneously, where multiple CFET tags, each with a different fluorescence signature, are used to label the different reactants which could include, for example, antibodies, antigens, ligands, or substrates.
Examples include antibody-antigen and receptor-ligand binding. In further examples, different reactants can be coupled to microspheres.
VI. CFET Tags Used in Ligation Assay to Identify Multiple Single Nucleotide Polymorphisms.
As an example of application for biological assays, the CFET tags were applied to an oligonucleotide ligation assay (Zandegren, 1988) coupled with solid phase purification to detect genetic mutations on exon 20 of the tumor suppressor retinoblastoma (RB1) gene. The schematic of the approach is shown in Fig.
11. Two 20 base-pair oligonucleotides, one labeled with a CFET tag at the 5' end and the other labeled with a biotin at the 3' end and a monophosphate (P) group at the 5' end, are hybridized to the target DNA
template such that the 3' end of the CFET-labeled oligonucleotide is positioned next to the 5' end of the biotinylated oligonucleotide. Taq DNA lipase joins the two juxtaposed oligonucleotides in a head-to-tail fashion by forming a phosphodiester bond, provided that the nucleotides at the ligating junction of the two oligonucleotides are correctly base-paired with the template (Barany, 1991). Under the experimental conditions using Taq DNA lipase, no ligation reaction occurs when there is a mismatch between the 3' end of the CFET-labeled probe (nucleotides A and C, Fig. 11) and the SNP site (nucleotides T and G, Fig. 11) on the target template. After the ligation, the CFET-labeled ligation products (40 base-pair) are immobilized to streptavidin-coated magnetic beads while the other components are washed away. The ligation products are then cleaved from the magnetic beads by denaturing the biotin-streptavidin interaction with formamide and analyzed with a three-color fluorescence CAE
system. The CFET-labeled ligation products are unambiguously detected due to their distinct mobility and unique fluorescence signatures in the electropherogram, see Figure 12. In the case of heterozygotes at the SNP site, two CFET tags with different fluorescence signature and electrophoretic mobility are used to label the oligonucleotides corresponding to each allele. The unique fluorescence signatures in the electropherogram thus identify each of the corresponding SNPs. The solid phase procedure completely eliminates the unligated CFET-labeled oligonucleotide. Although the unligated 20 base-pair biotinylated oligonucleotides are also captured by the magnetic beads, they do not produce fluorescence signals due to the absence of CFET tags. The CFET tag library in this application detects multiple SNPs on the target DNA template simultaneously.
Exon 20 of the tumor suppressor RB1 gene (Schubert, 1994) was selected as a model system to test the utility of the CFET tags. Several SNPs within a region of 200 base pairs in the RB1 gene have been found, which are well suited for evaluating a genetic mutation analysis system. Six ligation reactions were carried out separately using six different CFET tags on synthetic templates mimicking exon 20 of the RB1 gene where multiple SNPs (six nucleotide variations) are located. After the ligation and solid phase purification, the ligation products were combined in a single tube and analyzed with a three-color CAE
system, resulting in the simultaneous detection of six nucleotide variations by the unique fluorescence signatures of the CFET-labeled ligation products (see Figure 12A). The unique fluorescence signatures were spatially resolved in the electropherogram as a result of the different mobility of the CFET-labeled ligation products. In this model experiment, both CFET-1 (FAM) and CFET-6 (F-10-Cy5) detect homozygous SNPs (T/T). CFET-3 (F-9-T) and CFET-4 (F-13-T) clearly distinguish a mimic of RB1 gene mutation R661W (amino acid change from arginine to tryptophan due to mutation in codon 661) by detecting both the wild type (C) and~the mutation (T). CFET-7 (F-4-T-6-Cy5) and CFET-8 (F-7-T-7-Cy5) identify another mutation Q685P (amino acid change from glutamine to proline due to mutation in codon 685) with heterozygous genotype (A/C). To validate the CFET
technology further used three CFET-labeled oligonucleotide probes (CFET-1, 3 and 7) and their corresponding biotinylated oligonucleotides to identify three SNPs using a PCR product amplified from exon 20 of the RB1 gene from patient genomic DNA. The ligation reactions were performed in a single tube and the reaction products were loaded onto a three-color CAE system. Three individual homozygous SNPs (T, C and A), that were verified by DNA sequencing, were unambiguously identified by the three distinct fluorescence signatures from the CFET
tags (figure 12B): T (FAM, CFET-1), C (F-9-T, CFET-3) and A (F-4-T-6-Cy5, CFET-7). Thus, the approach described here can detect both heterozygotes and homozygotes unambiguously because of the unique CFET
fluorescence signature and mobility in the electropherogram.
To increase the level of control available in isolation other isolation-permitting moieties besides biotin may be employed such as phenylboronic acid.
Attachment of the moieties via cleavable linker S molecules enhances this still further.
VII. CFET Tags Used in Single Base Primer Extension to Identify Multiple Single Nucleotide Polymorphisms.
10 Single base extension for each dye-labeled primer was done by mixing 0.5 to 1 pmol of the primers with 1 pmol of template, followed by adding 2 u1 of thermo sequenase lOX reaction buffer (260 mM Tris-HCl, 65 mM
MgCl2, pH 9.5, Amersham Pharmacia Biotech, Piscataway, 15 NJ), 5 u1 of water, 1 pmol of biotinylated dideoxynucleoside triphosphates (Biotin-11-ddNTP, NEN, Boston, MA) and 1 unit of thermo sequenase in 20 mM Tris-HC1, pH 8.5, 50o glycerol, 0.1 mM
ethylenediamine tetraacetic acid (EDTA), 0.5% TweenTM_ 20 20 (v/v), 0.5o NonidetTM P-40 (v/v), 1mM
dithiothreitol (DTT), 100 mM KC1 and 0.053 unit/ul Thermoplasma acidophilum inorganic pyrophosphatase (Amersham Pharmacia Biotech). The reaction mixture was incubated at 54°C for 30 sec for single base 25 extension.
Schematic representation of the multiplex SNPs detection using CFET tags and biotinylated dideoxynucleotides is shown. in Figure 13. In this 30 example, extension of the primers are initiated by ddCTP-Biotin (for primer 1) and ddGTP-Biotin (for primer 2) in the presence of DNA polymerase if there is a match between the 3' end of the primer and the template (X and Y for primer 1; X' and Y' for primer 2). The extension products are isolated using streptavidin-coated magnetic beads. Upon denaturing, washing and releasing from the beads, the extension products are loaded onto an electrophoresis system and the resulting fluorescence signatures from the electropherogram identify each of the unique SNPs.
Thus, the CFET-labeled oligonucleotides, DNA
polymerase and biotinylated dideoxynucleotides form a high fidelity SNP detection system in which the base at the 3' end of the oligonucleotides dictates its extension by incorporating a specific biotinylated dideoxynucleotide. The CFET tags used were F, ~F-9-T.
and F-13-T. Their unique fluorescence signatures are shown in Figures 14 and 15 To increase the level of control over isolation, other isolation-permitting moieties such as phenylboronic acid, antigens or antibodies may be employed in place of the biotin. Attachment of the moieties via cleavable linker molecules enhances this still further.
VIII. High Throughput Analyses.
The throughput of the multiplex analyses offered by the use of the CFET tags can be increased by performing the analyses in the high throughput chamber illustrated in figure 16.
IX. In combination with non-FET tags.
To increase the number of different unique fluorescent signatures available in any set of tags CFET tags can be used in combination with single chromophore/fluorophore tags and tags with multiple chromophores/fluorophores where no FET occurs. The number of possible different fluorescence signatures using such combinations is huge, and would greatly aid multiplex analyses. Such fluorophores could be quantum dots, luminescent molecules of fluorescent dyes. For example, each tag could be used to detect a different SNP using the exemplified assays.
References U.S. Patent No. 6,028,190 issued February 222, 2000, Mathies et al.
Barany, F. (1991) Genetic disease detection and DNA
amplification using cloned thermostable ligase. PNAS.
88:189-193.
Benson, S. C., Mathies, R. A. & Glazer, A. N. (1993).
Heterodimeric DNA-binding dyes designed for energy transfer: stability and applications of the DNA
complexes. Nucleic Acids Res. 21: 5720-5726.
Benson, S. C., Singh, P. & Glazer, A. N. (1993).
Heterodimeric DNA-binding dyes designed for energy transfer: synthesis and spectroscopic properties.
Nucleic Acids Res. 21: 5727-5735.
Chee, M., Yang, R., Hubbell, E., Berno, A., Huang, X.
C., Stern, D., Winkler, J., Lockhart, D. J., Morris, M. S., Fodor, S. P. (1996). Accessing genetic information with high-density DNA arrays. Science.
274:610-614.
Chen, X. and Kwok, PY. (1997) Template-directed dye-terminator incorporation (TDI) assay: a homogeneous DNA diagnostic method based on fluorescence resonance energy transfer Nucl. Acids. Res. 25: 347-353.
Eggerding FA (1995) A one-step coupled amplification and oligonucleotide ligation procedure for multiplex genetic typing. PCR Methods Appl. 4: 337-345.
Fischer, S.G., Cayanais, E., de Fatima Bonaldo, M., Bowcock, A.M., Deaven, L.L., Edelman, I.S., Gallardo, T., Kalachikov, S., Lawton, L., Longmire, J.L., Lovett, M., Osborne-Lawrence, S., Rothstein, R., Russo, J.J., Soares, M.B., Sunjevaric, I., Venkatraj, V.S., Warburton, D., Zhang, P. and Efstratiadis, A.
(1996) A high-resolution annotated physical map of the human chromosome 13q12-13 region containing the breast cancer susceptibility locus BRCA2. Proc.
Natl. Acad. Sci. U.S.A. 93: 690-694.
Forster, T. (1965) In: Modern quantum Chemistry, Istanbul Lectures, Part III. Sinanoglu, O. (editor), Academic Press, New York, pp 93-137.
Glazer, A.N., Stryer, L. (1983) Fluorescent tandem phycobiliprotein conjugates. Emission wavelength shifting by energy transfer. Biophys. J. 43(3):383 386.
Hacia J.G., Edgemon K., Sun B., Stern D., Fodor S.A., Collins F.S. (1998). Two Color Hybridization Analysis Using High Density Oligonuleotide Arrays and Energy Transfer Dyes Nucleic Acids Research 15; 26: 3865-6 Ju, J., Glazer, A.N. & Mathies, R.A. (1996) Cassette labeling for facile construction of energy transfer fluorescent primers. Nucleic Acids Res. 24, 1144 1148.
Ju J, Glazer AN and Mathies RA (1996) Energy transfer primers: A new fluorescence labeling paradigm for DNA
sequencing and analysis. Nature Medicine 2: 246-249.
5 Ju J, Ruan C, Fuller CW, Glazer AN and Mathies RA
(1995) Energy transfer fluorescent dye-labeled primers for DNA sequencing and analysis. Proc. Natl.
Acad. Sci. USA 92: 4347-4351.
10 Ju J, Yan H, Zaro M, Doctolero M, Goralski T, Konrad K, Lachenmeier E and Cathcart R (1997) DNA sequencing with solid phase captureable terminators. Microb.
Comp. Genomics 2: 223.
15 Kalachikov, S. et al. (1997) Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics 42(3): 369-377.
Landegren U, Kaiser R, Sanders J and Hood L (1988) A
20 ligase-mediated gene detection technique. Science 241: 1077-1080.
Lee LG, Spurgeon SL, Heiner CR, Benson SC, Rosenblum BB, Menchen SM, Graham RJ, Constantinescu A, Upadhya 25 KG and Cassel JM (1997) New energy transfer dyes for DNA sequencing. Nucleic Acids Res. 25: 2816-2822.
Lohmann DR (1999) RB1 gene mutations in retinoblastoma. Hum Mutat. 14: 283-288 Maxam AM and Gilbert W (1977) A new method for sequencing DNA. Proc Natl. Acad. Sci. USA 74: 560-564.
Munne S, Magli C, Bahce M, Fung J, Legator M, Morrison L, Cohert J, Gianaroli. (1998) Preimplantation diagnosis of the aneuploidies most commonly found in spontaneous abortions and live births: XY, 13, 14, 15, 16, 18, 21, 22. Prenat Diagn.
18: 1459-66.
Qu, X., Hauptschein, R.S., Rzhetsky, A., Scotto, L., Chien, M., Ye, X., Frigeri, F., Rao, P.H., Pasqualucci, L., Gamberi, B., Zhang, P., Chaganti, R.S.K., Dalla-Favera, R. and Russo, J.J. (1998) Analysis of a 69 kb contiguous genomic sequence at a putative tumor suppressor gene locus on human chromosome 6q27. DNA Seq. 9: 189-204.
Rosenblum, B.B., Lee, L.G., Spurgeon, S.L., Khan, S.H., Menchen, S.M., Heiner, C.R., Chen, S.M.(1997).
New dye-labeled terminators for improved DNA
sequencing patterns. Nucleic Acids Res 25: 4500-4 Rye, H. S., Drees, B. L., Nelson, H. C. M. & Glazer, A. N. (1993). Stable fluorescent dye-DNA complexes in high sensitivity detection of protein-DNA
interactions. Application to heat shock transcription factor. J. Biol. Chem. 268: 25229-25238.
Sambrook et al., "Molecular Cloning: A Laboratory Manual", Second Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
Sanger F, Nickeln S and Coulson AR (1977) DNA
sequencing with chain-terminating inhibitors. Proc.
Natl. Acad. Sci. USA 74: 5463-5467.
Saxon E and Bertozzi CR (2000), Cell Surface Engineering by a Modified Staudinger Reaction.
Science, 287; 2007-2010.
Schena, M., Shalon D., Davis, R. and Brown P.~.
(1995) Quantitative monitoring of gene expression patterns with a cDNA microarray. Science 270:467-470.
Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Yand Ried T (1996) Multicolor spectral karyotyping of human chromosomes.
Science 273: 494-497.
Schubert EL, Hansen MF and Strong LC (1994). The retinoblastoma gene and its significance. Ann Med.
26: 177-184.
Smith, L. M., Sanders, J.2., Kaiser, R. J., Hughes, P., Dodd, C., Connell, C. R., Heiner, C., Kent, S.B.H. and Hood, L. E. (1986). Fluorescence detection in automated DNA sequencing analysis. Nature. 321:
674-679.
Speicher MR, Ballard SG and Ward DC (1996) Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genet. 12: 368-375.
Stryer, L. (1978) Fluorescence energy transfer as a spectroscopic ruler. Annu. Rev. Biochem. 47: 819-846.
Tabor, S. & Richardson, C. C. A single residue in DNA
polymerases of the Escherichia coli DNA polymerase I
family is critical for distinguishing between deoxy-and dideoxyribonucleotides. 1995. Proc. Natl. Acad.
Sci. U.S.A. 92: 6339-6343.
Uetz, et al; and S. Fields (2000) A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 403 (Number 6770) 623 - 627.
Vogel. (1989) Textbook Of Practical Organic Chemistry, Fifth Edition, Addison Wesley Longman, Harlow, U.K.
Wu DY and Wallace RB (1989) The ligation amplification reaction (LAR): Amplification of specific DNA sequences using sequential rounds of template-dependent ligation. Genomics 4: 560-569.
Xu, G-L. wt al. (1999) Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402: 187-191.
Zhu Z ; Chao J ; Yu H ; Waggoner AS ( 1994 ) . Directly labeled DNA probes using fluorescent nucleotides with different length linkers. Nucleic Acids Res, 22:
3418-22.
SEQUENCE LISTING
<110> Ju, Jingyue Russo, James J
Tong, Anthony Li, Zengmin <120> Combinatorial Fluoresence Energy Transfer Tags And Their Applications For Multiplex Biological Analyses <130> 0575/62238A/JPW/ADM
<140>
<141>
<150> 09/658,077 <151> 2000-09-11 <l60> 17 <170> Patentln Ver. 2.1 <210> 1 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: scaffold <400> l tttttttttt tttttttttt tttttc 26 <210> 2 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <900> 2 ttaaaaagaa taagggtgtc 20 <210> 3 <21I> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 3 acatagccga tcggatagag 20 <210> 4 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 4 tcatagccga tcggatagag gc 22 <210> 5 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 5 acatagccga tcggatagag 20 <210> 6 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <900> 6 gccgatttat gtgaaacact tgcg 24 <210> 7 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 7 accgatttat gtgaaacact tgcgga 26 <210> 8 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 8 cggaagacag actcgtgggt 20 <210> 9 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 9 cttaatcttg tatagtagac ctgggaaa 28 <210> 10 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 10 attaatcttg tatagtagac ctgggaaaag 30 <210> 11 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 1l atagtagacc tgggaaaagg 20 <210> 12 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 12 tcgtgtggga cgtcttactc atacttgagt 30 <210> 13 <211> 32 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <900> 13 gcgtgtggga cgtcttactc atacttgagt ac 32 <210> 14 <211> 100 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: template <400> 14 gtaaaaatga ctaatttttc ttattcccac agtgtatcgg ctagcctatc tccggctaaa 60 tacactttgt gaacgccttc tgtctgagca cccagaatta 100 <210> 15 <211> 100 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: template <400> 15 gtaaaaatga ctaatttttc ttattcccac agagtatcgg ctagcctatc tctggctaaa 60 tacactttgt gaacgccttc tgtctgagca cccagaatta 100 <210> 16 <211> 100 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: template <400> 16 tacactttgt gaacgccttc tgtctgagca cccagaatta gaacatatca tctggaccct 60 tttccagcac accctgcaga atgagtatga actcatgaga 100 <210> 17 <211> 100 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: template <400> 17 tacactttgt gaacgccttc tgtctgagca cccataatta gaacatatca tctggaccct 60 tttcccgcac accctgcaga atgagtatga actcatgaga 100
This invention further provides the instant composition of matter, wherein m is 4.
This invention also. provides a nucleic acid labeled with any of the instant compositions.
This invention provides any of the instant compositions, wherein the nucleic acid is DNA.
This invention provides any of the instant compositions, wherein the nucleic acid is RNA.
This invention provides any of the instant compositions, wherein the nucleic acid is DNA/RNA.
This invention also provides a method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:
(a) contacting the nucleic acid, under hybridizing and DNA ligation-permitting conditions, with (i) a DNA ligase, (ii) a first oligonucleotide having affixed thereto a composition of matter of claim 1 wherein the first oligonucleotide hybridizes with nucleotides immediately adjacent one side of the predetermined position and (iii) a second oligonucleotide which hybridizes with the nucleotides immediately adjacent the other side of the predetermined position, wherein the hydroxy-terminal residue of the oligonucleotide which hybridizes to the nucleotide located 3' of the predetermined position is a nucleotide which is complementary to the preselected nucleotide residue; and (b) detecting the presence of a ligation product comprising both the first and the second oligonucleotides, the presence of such a ligation product indicating the presence of the preselected nucleotide z5 residue at the predetermined position.
This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected 30 nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.
This invention provides the instant method, wherein the presence of a plurality of given nucleotide residues is determined simultaneously.
This invention further provides the instant method, wherein the DNA ligase is Taq DNA ligase.
This invention further provides the instant method, wherein the second oligonucleotide has an isolation-permitting moiety affixed thereto, and wherein the method further comprises the steps of isolating the moiety-containing molecules resulting from step (a) and determining the presence therein of ligated first and second oligonucleotides.
This invention further provides the instant method, wherein the composition of matter affixed to the first oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of ligated first and second oligonucleotides in step (b).
This invention also provides a method of determining whether a. preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of: ' (a) contacting the nucleic acid, under hybridizing and DNA polymerization-permitting conditions, with (i) a DNA polymerase, (ii) an oligonucleotide (1) having affixed thereto a composition of matter of claim 1, and (2) having a hydroxyl 3' terminus thereof, wherein the oligonucleotide hybridizes with the 3' region of the nucleic acid molecule flanking the predetermined position, and (iii) a dideoxynucleotide labeled with an isolation permitting moiety, wherein the labeled dideoxynucleotide is complementary to the given nucleotide residue, with the proviso that upon hybridization of the oligonucleotide with the nucleic acid in the presence of DNA polymerase and the preselected nucleotide residue, the oligonucleotide and dideoxynucleotide are juxtaposed so as to permit their covalent linkage by the DNA polymerase;
(b) detecting the presence of a polymerization product comprising both the oligonucleotide and the dideoxynucleotide, the presence of such a polymerization product indicating the presence of the preselected nucleotide residue at the predetermined position.
This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.
This invention further provides the instant method, wherein the DNA polymerase is thermo sequenase.
This invention further provides the instant method, wherein the dideoxynucleotide is selected from the group consisting of dideoxyadenosine triphosphate, dideoxycytidine triphosphate, dideoxyguanosine triphosphate, dideoxythymidine triphosphate, and dideoxyuridine triphosphate.
This invention further provides the instant method, wherein the composition of matter affixed to the oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of polymerization product in step (b).
This invention further provides the instant methods, wherein observing the predetermined emission spectrum is performed using radiation having a wavelength of between 200 and 1000nm.
This invention further. provides the instant methods, wherein the radiation has a wavelength of 488 nm.
This invention further provides the instant methods, wherein observing the predetermined emission spectrum 5 is performed using radiation having a bandwidth of between 1 and 50nm.
This invention further provides the instant methods, wherein the radiation bandwidth is lnm.
This invention further provides the instant methods, wherein the isolation-permitting moiety comprises biotin, streptavidin, phenylboronic acid, salicylhydroxamic acid, an antibody or an antigen.
This invention further provides the instant methods, wherein the isolation-permitting moiety is attached to the oligonucleotide via a linker molecule.
This invention further provides the instant methods, wherein the isolation-permitting moiety is attached to the dideoxynucleotide via a linker molecule.
This invention further provides the instant methods, wherein the linker molecule is chemically cleavable.
This invention further provides the instant methods, wherein the linker molecule is photocleavable.
This invention further provides the instant methods, wherein the linker molecule has the structure:
H
~ N
I IO
O.
Brief Description Of The Figures Figure 1A-B: (A) Schematic of a multi-chromophore assembly connected to a linker. In general, 1 to n chromophores can be attached to the assembly with the chromophores separated by spacers as shown.
Chromophores can be, but not limited to, fluorescent dyes, quantum dots or luminescent molecules such as terbium chelate. A variety of spacers such as nucleotides, peptides, a polymer linker formed by 1', 2'-dideoxyribose phosphates or other chemical moieties can be used. The assembly label shown here is connected to a linker which can be designed as nucleic acids, proteins or cells, etc for multiplex biological assays. (B) The synthesis of F-4-T-6-C.
The numbers in F-4-T-6-C refer to the number of spacing nucleotides in the scaffold between dyes F
and T, and T and C. F = Fam; T - Tam; C = Cyanine 5 monofunctional dye.
Figure 2A-D: Spectroscopic data for tags F-4-T-6-C
and F-7-T-3-C.
(A) Two tags with different fluorescent signatures have been constructed by varying the spacing between the three dyes F, T, and C.
(B) Ultraviolet/visible (UV/vis) absorption spectrum of dye F-4-T-6-C.
(C) Fluorescence emission spectra of dye F-4-T-6-C.
(D) Fluorescence emission spectra of dye F-7-T-3-C.
F = Fam; T = Tam; C = Cy5.
Figure 3A-B: Schematic labeling approach to construct CFET-primers and CFET-dUTPs. The spacer between dyes is 1',2'-dideoxyribose phosphate (S) in (A) and proline (P) in (B). "m" and "n" refer to the number of molecules in the spacer. dUTP
deoxyuridine triphosphate.
Figure 4: The synthesis of CFET-dUTP. The CFET tag comprises three different fluorescent dyes: Fam, Tam and Cy5.
Figure 5: Structures of Aminoallyl (AA)-dUTP, Fam-proline, and N-Hydroxy succinimide (NHS) esters of TAM and CyS.
Figure 6: Synthetic schemes to prepare Fam-proline, Azido-proline and Cy5-phosphine. TMSCI -trimethylsilyl chloride.
Figure 7: The eight unique fluorescence signatures of CFET tags generated in a three-color CAE system. FAM
channel (520 -~- 20 nm, dotted line), TAM channel (585 ~ 20 nm, solid thin line), Cy5 channel (670 ~ 20 nm, solid thick line). The digital ratio denoting the fluorescence signature for each CFET tag from the three channels [dotted:thin:thick] is shown in the brackets. The fluorescence signatures in the electropherogram were obtained by excitation at 488 nm and electrokinetic injection of the eight CFET-labeled oligonucleotides into the three-color CAE
system.
Figure 8A-B: Schematic of using ligase chain reaction for determining the genotype at a locus containing a possible single-base mutation.
(A) Primer pairs are generated surrounding a base that can be mutated. The wild-type primer is labeled with one CFET tag (Tag 1) and the mutation-specific primer with another CFET tag (Tag 2) .
(B) Subsequent gel electrophoresis allows separation of ligated primer pairs and unincorporated primers. Different bands appear. on the gel depending on whether the template is wild-type or mutated.
Figure 9: Schematic of expected results from screening four potential mutation sites of Rb1 gene using eight unique CFET Tags and the ligase chain reaction assay. Only ligation products are shown on the gels.
Figure 10: Schematic of chromosomal studies to detect macrodeletions and amplifications.
Figure 11: This figure schematically shows the procedure for multiplex SNP detection through the ligation of hybridized CFET-labeled and biotinylated oligonucleotides. Taq DNA ligase seals the nick between the two hybridized oligonucleotides if the nucleotides at the ligating junction are correctly base-paired to the template (A to T; C to G). CFET-labeled, biotinylated ligation products are them isolated using streptavidin-coated magnetic beads.
After washing and releasing from the magnetic beads, the ligation products are electrokinetically injected into a three-color CAE system. Each CFET-labeled ligation product, which identifies a unique SNP, is unambiguously detected due to its distinct mobility 5 and fluorescence signature in the CAE
electropherogram.
Figure 12A-B: Electropherogram of CFET-labeled ligation products for SNPs identification on exon 20 10 of the RB1. (A) Detection of six nucleotide variations from synthetic DNA templates. FAM (T) and F-10-Cy5 (T) peaks are obtained from two different locations of the same template. F-9-T (C) and F-13-T
(T) peaks indicate mutations from the same locus of a 15 DNA template, while F-4-T-6-Cy5 (A) and F-7-T-7-Cy5 (C) peaks identify mutations from the same locus of another DNA template. (B) Detection of three homozygous genotypes (T, C and A) from a PCR product of RB1.
Figure 13: This figure is a schematic of single base primer extension for multiplex SNP detection by using dye-labeled primers and biotinylated dideoxynucleoside triphosphates (ddNTP-Biotin). DNA
template containing polymorphic sites is incubated with a dye-labeled primer, hybridizing the template adjacent to the polymorphic site, ddNTP-Biotin and thermo sequenase. At the end of reaction and purification the primer extension products are analyzed for fluorescence signatures.
Figure 14: Three unique fluorescence signatures generated from dye-labeled extension products. FAM
channel (light) and TAM channel (Dark). The fluorescence signatures in the electropherograms were obtained by excitation at 488nm and the single base extension of the dye-labeled primers. The digital ratio denoting the fluorescence signature for each from the two detection channels is shown in parentheses.
Figure 15A-C: The electropherograms of CFET-labeled primer extension products for multiplex SNPs identification on the mimic of exon 20 of the RB1.
FAM channel (Light line) and TAM channel (Dark line).
(A): Detection of two individual homozygous genotypes from a wild type template. FAM (T) and F-9-T (C) peaks were obtained from two different loci on the template. (B): Similar to (A) except a mutated template was used. (C): Simultaneous detection of three nucleotide variations. FAM (T) peak was obtained from a locus of the template where a homozygous genotype was found. F-9-T (C) and F-13-T
(T) peaks indicate the mutation R661W (heterozygote) from the same locus of a DNA template.
Figure 16: Schematic of a high throughput channel based, moiety-based purification system. Sample solutions can be pushed back and forth between the two plates through glass capillaries and the coated channels in the chip, the channels being coated with an appropriate chemical to bind the moiety tag on the samples, e.g. streptavidin coating in the case of biotinylated oligonucleotides. Where the moieties are attached by cleavable linkers, e.g. photocleavable linkers, the whole chip can be irradiated to cleave the samples after immobilization.
Detailed Description Of The Invention Definitions The following definitions are offered as an aid to understanding the invention:
CAE - Capillary Array Electrophoresis CFET - Combinatorial fluorescence energy transfer;
Cy 5 - Cyanine 5 monofunctional dye;
ddNTP - Dideoxynucleotide trisphosphate;
FAM - 6-carboxyfluorescein;
nm - nanometer RB1 - Retinoblastoma gene;
SNP - Single nucleotide polymorphism;
TAM - N,N,N',N'-tetramethyl-6-carboxy rhodamine.
As used herein, and unless stated otherwise, each of the following terms shall have the definition set forth below.
"Chemically cleavable" shall mean cleavable by any chemical means including but not limited to pH and temperature.
"DNA/RNA" shall mean a nucleic acid molecule comprising both deoxyribonucleotides and ribonucleotides.
"Emission spectrum" shall mean the amplitude and frequency of energy emitted from a composition of matter as a result of exciting radiation thereon.
"Flexible", when used to describe a molecular scaffold, shall mean that the distance between the centers of any pair of fluorophores covalently bound to the scaffold varies by more than 50%.
"Fluorescence energy transfer" shall mean the transfer of energy between two fluorophores via a dipole-dipole interaction.
"Fluorescent dye" shall mean an organic dye molecule capable of emitting fluorescent energy of wavelength between 200 and 1000nm when excited by an energy of shorter wavelength wherein the emitted energy results from a singlet to singlet transition. Examples are 6-carboxyfluorescein, N,N,N',N'-tetramethyl-6-carboxyrhodamine, and cyanine-5 monofunctional dye.
"Fluorophore" shall mean a molecule, such as a fluorescent dye, quantum dot or luminescent molecule, capable of emitting energy of wavelength between 400 and 1000nm when excited by an energy of shorter wavelength than the corresponding emission wavelength. Examples of fluorophores include 6-carboxyfluorescein, N,N,N',N'-tetramethyl-6-carboxy rhodamine, cyanine-5 monofunctional dye, zinc sulfide-capped cadmium selenide quantum dots, and lanthanide chelates.
"Hybridize" shall mean the annealing of one single-stranded nucleic acid molecule to another single stranded nucleic acid molecule based on sequence complementarity. The propensity for hybridization between nucleic acids depends on the temperature and ionic strength of their milieu, the length of the nucleic acids and the degree of complementarity. The effect of these parameters on hybridization is well 5 known in the art (see Sambrook, 1989).
"Isolation-permitting moieties" shall include without limitation biotin or streptavidin which bind to one another, antibodies or antigens which bind to one 10 another, phenylboronic acid or salicylhydroxamic acid which bind to one another.
"Ligation-permitting conditions" include without limitation conditions of temperature, ionic strength, 15 ionic composition, molecular composition, orientation and viscosity that allow one oligonucleotide to be joined enzymatically to another via a phosphodiester bond.
20 "Ligation" shall mean the enzymatic covalent joining of a nucleic acid with either another nucleic acid or a single nucleotide.
"Linker molecule" shall mean a chemical group used to 25 covalently join two other molecules. An example of a linker molecule is the structure given below:
H
N
"Luminescent molecule" shall mean a molecule capable of emitting energy of wavelength between 200 and 1000nm when excited by energy of shorter wavelength than the corresponding emission wavelength, wherein the emitted energy does not result from a singlet to singlet transition. Examples of luminescent molecules include europium polycarboxylate chelate and terbium chelates.
"Molecular scaffold" shall mean a molecular structure to which two or more fluorophores can be, and/or are, covalently bound at discrete loci thereon. Ideally, a molecular scaffold is polymeric, comprising monomeric units to which fluorophores can be bound. The monomeric units which make up such polymeric scaffold can, but need not be; identical. Examples of such monomeric units include 1',2'-dideoxyribose phosphate and thymidine.
"Nucleic acid molecule" shall mean any nucleic acid molecule, including, without limitation, DNA, RNA and hybrids thereof. The nucleic acid bases that form nucleic acid molecules can be the bases A, C, G, T
and U, as well as derivatives thereof. Derivatives of these bases are well known in the art, and are exemplified in PCR Systems, Reagents and Consumables (Perkin Elmer Catalogue 1996-1997, Roche Molecular Systems, Inc., Branchburg, New Jersey, USA).
"Oligonucleotide" shall mean a nucleic acid comprising two or more nucleotides.
"Photocleavable" shall mean cleavable by electromagnetic energy of between 200 and 1000nm wavelength.
"Polymeric" shall describe a molecule composed of more than two monomeric units.
"Quantum dot" shall mean a nanometer-sized composition of matter comprising a semi-conductor or metal, wherein such composition is capable of luminescence. Examples of quantum dots include zinc-sulfide-capped cadmium selenide quantum dots.
"Rigid", when used to describe a molecular scaffold, shall mean that the distance between the centers of any pair of fluorophores covalently bound to the scaffold does not vary more than 500.
Embodiments of the Invention This invention provides a composition of matter comprising multiple fluorophores, each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer between one such fluorophore and another such fluorophore, wherein the one such fluorophore and the another such fluorophore are characterized by the maximum emission wavelength of one being greater than the minimum excitation wavelength of the other.
This invention further provides the instant composition of matter comprising two fluorophores, each of which is bound to a molecular scaffold, at a separate predetermined position on the scaffold, such separate positions being selected so as to permit fluorescence energy transfer between sucn fluorophores, and such fluorophores being characterized by the maximum emission wavelength of one of the fluorophores being greater than the minimum excitation wavelength of the other fluorophore.
This invention further provides the instant composition of matter comprising three fluorophores each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer among such fluorophores and such fluorophores being characterized by the maximum emission wavelength of one such fluorophore being greater than the minimum excitation wavelength of the second such fluorophore and the maximum emission wavelength of such second fluorophore being greater than the minimum excitation wavelength of the third such fluorophore.
In one embodiment each fluorophore is covalently bound to the molecular scaffold.
In one embodiment the efficiency of the fluorescence energy transfer is less than 200.
In one embodiment the molecular scaffold is rigid.
In one embodiment the molecular scaffold is polymeric.
In one embodiment the molecular scaffold comprises a nucleic acid.
In one embodiment the molecular scaffold comprises a peptide.
In one embodiment the molecular scaffold comprises a polyphosphate.
In one embodiment at least one fluorophore is a fluorescent dye.
In one embodiment the fluorescent dye is 6-carboxyfluorescein.
In one embodiment the fluorescent dye is N,N,N',N'-tetramethyl-6-carboxyrhodamine.
In one embodiment the fluorescent dye is cyanine-5 monofunctional dye.
In one embodiment at least one fluorophore is a luminescent molecule.
In one embodiment at least one fluorophore is a quantum dot.
This invention also provides a composition of matter having the structure:
FAM TAM
Q- T -(S)m T -R
wherein S represents a 1',2'-dideoxyribose 10 phosphate moiety, m is an integer greater than 1 and less than 100, each T represents a thymidine derivative, FAM represents 6-carboxyfluorescein derivative, TAM represents N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line 15 represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
20 In one embodiment m is 4. In one embodiment m is 6.
In one embodiment m is 9. In one embodiment m is 13.
This invention also provides a composition of matter having the structure:
FAM Cy5 Q_ T - ~S)mrT_R
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
In one embodiment m is 4. In one embodiment m is 5.
In one embodiment n m is 7. In one embodiment m is 10. In one embodiment m is 13.
This invention. also provides a composition of matter comprising the structure shown below:
FAM TAM Cy5 Q T WS)rWT -~S)n-T-R
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, n is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that~R and Q
are different.
In one embodiment m is 3, and n is 7. In one embodiment, wherein m is 4, and n is 6. In one embodiment m is 5, and n is 5. In one embodiment m is 6, and n is 6. In one embodiment m is 7, and n is 7.
This invention also provides a composition of matter comprising the structure shown below:
TAM TAM
Q_ T -(S)m T-R
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m represents an integer greater than 1 and less than 100, T represents a thymidine derivative, and TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q
are different.
In one embodiment m is 4.
This invention also provides a nucleic acid labeled with any of the instant compositions.
In one embodiment the nucleic acid is DNA.
In one embodiment the nucleic acid is RNA.
In one embodiment the nucleic acid is DNA/RNA.
This invention also provides a method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:
(a) contacting the nucleic acid, under hybridizing and DNA ligation-permitting conditions, with (i) a DNA ligase, (ii) a first oligonucleotide having affixed thereto a composition of matter of claim 1 wherein the first oligonucleotide hybridizes with nucleotides immediately adjacent one side of the predetermined position and (iii) a second oligonucleotide which hybridizes with the nucleotides immediately adjacent the other side of the predetermined position, wherein the hydroxy-terminal residue of the oligonucleotide which hybridizes to the nucleotide located 3' of the predetermined position is a nucleotide which is complementary to the preselected nucleotide residue; and (b) detecting the presence of a ligation product comprising both the first and the second oligonucleotides, the presence of such a ligation product indicating the presence of the preselected nucleotide residue at the predetermined position.
This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.
In one embodiment the presence of a plurality of given nucleotide residues is determined simultaneously.
In one embodiment the DNA ligase is Taq DNA ligase.
This invention further provides the instant method, wherein the second oligonucleotide has an isolation-permitting moiety affixed thereto, and wherein the method further comprises the steps of isolating the moiety-containing molecules resulting from step (a) and determining the presence therein of ligated first and second oligonucleotides.
This invention further provides the instant method, wherein the composition of matter affixed to the first oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of ligated first and second oligonucleotides in step (b) .
This invention also provides a method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:
5 (a) contacting the nucleic acid, under hybridizing and DNA polymerization-permitting conditions, with (i) a DNA polymerase, (ii) an oligonucleotide (1) having affixed thereto a composition of matter of claim l, and (2) having 10 a hydroxyl 3' terminus thereof, wherein the oligonucleotide hybridizes with the 3' region of the nucleic acid molecule flanking the predetermined position, and (iii) a dideoxynucleotide labeled with an isolation-15 permitting moiety, wherein the labeled dideoxynucleotide is complementary to the given nucleotide residue, with the proviso that upon hybridization of the oligonucleotide with the nucleic acid in the 20 presence of DNA polymerase and the preselected nucleotide residue, the oligonucleotide and dideoxynucleotide are juxtaposed so as to permit their covalent linkage by the DNA polymerase;
(b) detecting the presence of a polymerization 25 product comprising both the oligonucleotide and the dideoxynucleotide, the presence of such a polymerization product indicating the presence of the preselected nucleotide residue at the predetermined position.
This invention further provides a method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the instant method.
In one embodiment the DNA polymerase is thermo sequenase.
This invention further provides the instant method, wherein the dideoxynucleotide is selected from the group consisting of dideoxyadenosine triphosphate, dideoxycytidine triphosphate, dideoxyguanosine triphosphate, dideoxythymidine triphosphate, and dideoxyuridine triphosphate.
This invention further provides the instant method, wherein the composition of matter affixed to the oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of polymerization product in step (b).
This invention further provides the instant methods, wherein observing the predetermined emission spectrum is performed using radiation having a wavelength of between 200 and 1000nm.
In one embodiment the radiation has a wavelength of 488 nm.
This invention further provides the instant methods, wherein observing the predetermined emission spectrum is performed using radiation having a bandwidth of between 1 and 50nm.
In one embodiment the radiation bandwidth is lnm.
This invention further provides the instant methods, wherein the isolation-permitting moiety comprises biotin, streptavidin, phenylboronic acid, salicylhydroxamic acid, an antibody or an antigen.
This invention further provides the instant methods, wherein the isolation-permitting moiety is attached to the oligonucleotide via a linker molecule.
This invention further provides the instant methods, wherein the isolation-permitting moiety is attached to the dideoxynucleotide via a linker molecule.
This invention further provides the instant methods, wherein the linker molecule is chemically cleavable.
This invention further provides the instant methods, wherein the linker molecule is photocleavable.
This invention further provides the instant methods, wherein the linker molecule has the structure:
~ N
I'O
O;
This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.
Experimental Details I. The Design of Combinatorial Fluorescence Energy Transfer Tags Background: Optical interactions persist between two chromophores even when they are as far as 80 angstroms apart. The chromophore with high energy absorption is defined as a donor, and the chromophore with lower energy absorption is defined as an acceptor. Fluorescence energy transfer is mediated by a dipole-dipole coupling between the chromophores that results in resonance transfer of excitation energy from an excited donor molecule to an acceptor (Forster, 1965). Forster established that the energy transfer efficiency is proportional to the inverse of the sixth power of the distance between the two chromophores. Fluorescence resonance energy transfer has been used extensively as a spectroscopic ruler for biological structures (Stryer, 1978), and energy transfer-coupled tandem phycobiliprotein conjugates have found wide applications as unique fluorescent labels (Glazer and Stryer, 1983). A set of polycationic heterodimeric fluorophores that exploit energy transfer and have high affinities for double-stranded DNA were also developed, offering advantages over monomeric fluorophores in multiplex fluorescence labeling applications (Benson et al., 1993; Rye et al., 1993). By exploiting fluorescence energy transfer principle, using a common donor and four different acceptors, tour sets of ET primers and dideoxynucleotides were constructed that are markedly superior to single dye labels in DNA sequencing, and in multiplex polymerase chain reaction (PCR)-based mapping and sizing protocols (Ju et al., 1995, 1996).
The present application discloses how energy transfer 5 and combinatorial concepts can be used to tune the fluorescence emission signature of fluorescent tags for the development of a large number of combinatorial fluorescence energy transfer (CFET) tags. A schematic construction of the tags is shown 10 in Figure 1a. Representative examples for the construction of the CFET tags and their expected fluorescence signatures are shown in Table 1. Three individual fluorescent dyes, 6-carboxyfluorescein (FAM or F), N,N,N',N'-tetramethyl-6-carboxyrhodamine 15 (TAM or T) and Cyanine dye (Cy5 or C) are selected as examples to construct the CFET tags. The fluorescence emission maxima for FAM, TAM and Cy5 are 525nm, 580nm and 670nm, respectively. Chemical moieties used as spacers are selected to construct 20 various CFET tags aimed at conveniently labeling biomolecules and other targets of interest, monomers are convenient to employ. Other spacer moieties include nucleotides, peptides and 1'2'-dideoxyribose phosphates. As shown in Table 1, tag 1 is constructed 25 with FAM alone and displays its characteristic fluorescence signature (?Amax - 525 nm). Any fluorophore with a characteristic fluorescence signature could be used in place of FAM. With FAM as a donor and TAM as an acceptor, CFET tags 2, 3, 4, 30 and 5 can be constructed by changing the distance "R"
between the FAM and TAM chromophores. The rationale is that altering the distance between donor and acceptor changes the energy transfer efficiency, and therefore the ratio of the fluorescence emission intensity of the donor (FAM) and acceptor (TAM).
Similarly, with FAM as a donor and Cy5 as an acceptor, CFET tags 6, 7 and 8 can be generated.
With three dyes, with FAM as a donor, TAM as an acceptor for FAM and as a donor for Table 1 Representative Example of CFET Tags CFET Tag Fluorescence Tag ID
Signature F 525 nm R ' 525 nm 580 nm ' F
~
r~~
R
T
525 nm 580 nm F~ R T
525 nm 580 nm R~
F T
525 nm 580 nm 525 nm 670 nm r i F C 525 nm 670 nm F G
525 nm 670 nm F R' T ~ C
525 nm 580 nm 670 nm FTC . 10 525 nm 580 nm 670 nm Cy5, which acts as the final acceptor, CFET tags 9 and 10 can be constructed by manipulating distances "R1" and "R2". All the CFET tags can be excited with a single laser source and analyzed by simple detectors capable of capturing the emission signatures from each tag. In other embodiments, more than three dyes can be used. Alternatively just single chromophores can be used as long as they have unique fluorescence signatures.
The donor and acceptor fluorescent molecules are separated using convenient chemical moieties as spacers to tune the fluorescence signatures of the CFET tags. Examples of such spacer moieties include nucleotides, dideoxyribose phosphate, and amino acids. The construction of CFET tags involving three or more different dyes is more challenging, since synthetic procedures need to be designed for introducing the individual dye molecules at specific locations on the spacing backbone. As an example, CFET tags involving three dyes can be constructed using oligonucleotides as spacers. An oligonucleotide with the sequence 5'-TTTTTTTTTTTTTTTTTTTTTTTTTC-3' (SEQ ID NO: 1) was selected as a scaffold to covalently attach FAM, TAM and CyS. FAM is introduced by using a 6-FAM-dT phosphoramidite, TAM
is introduced by using TAM-dT (Glen Research, Sterling, VA), and a modified T having an amino linker at the C-5 position (Glen Research) is incorporated into the oligonucleotide which is then linked to Cy5 - N-Hydroxy succinimide (NHS) ester.
The final product is purified by size exclusion chromatography and gel electrophoresis. A
representative reaction for the construction of CFET
tag F-4-T-6-C (the numbers refer to the number of spacing nucleotides) involving FAM, TAM and Cy5 is shown in Figure 1. By changing the spacing between FAM and TAM, and TAM and Cy5, two CFET tags F-4-T-6-C
and F-7-T-3-C with the fluorescence signatures corresponding to tags 9 and 10 have been constructed as shown in Figure 2. Shown are the ultraviolet/visible absorption spectrum of F-4-T-6-C
(Figure 2B) as well as the fluorescence emission spectra for F-4-T-6-C and F-7-T-3-C (Figures 2C and 2D), with excitation at 488 nm (1x Tris-Borate-Ethylenediaminetetraacetic acid (TBE) solution). The UV/visible spectrum exhibits the characteristic absorption of FAM at 495 nm, TAM at 555 nm and Cy5 at 649 nm (Figure 2B). The fluorescence emission spectrum of F-4-T-6-C displays a fluorescence signature with Cy5 highest, TAM next and FAM lowest;
whereas F-7-T-3-C displays a fluorescence signature with FAM highest, TAM next and Cy5 lowest. The two fluorescence signatures are clearly different, and easily discernible by spectroscopic methods. Here the feasibility of the CFET approach involving three different dyes is clearly demonstrated.
It is evident that one can synthesize broad families of CFET tags. Examples of two synthetic approaches for constructing CFET tags are shown: (1) 1',2'-dideoxyribose phosphate monomer can be used as a spacer to separate dyes used for labeling oligonucleotide primers, which can be assembled on a DNA synthesizer; (2) a rigid peptide linker can be used to construct a CFET cassette to label any other molecular targets.
The first example is shown in Figure 3A. A polymer 5 linker (SSS...SSSS) formed by 1' , 2' -dideoxyribose phosphates (S) at the 5' end of the desired primer sequence forms a universal spacer for attaching the ET-coupled fluorophores, thereby producing an ET
cassette. The 1',2'-dideoxyribose phosphates can be 10 introduced using 5'-dimethoxytrityl-1',2'-dideoxyribose-3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (dSpacer CE Phosphoramidite, Glen Research, Sterling, VA). dSpacer CE Phosphoramidite has previously been used to construct DNA sequencing 15 primers (Ju et al., 1996). In this CFET tag construction, FAM is used as a common donor. In a CFET tag consisting of two different fluorescent dyes, either TAM or Cy5 can be used as acceptors;
whereas in a CFET tag consisting of three different 20 fluorescent dyes, TAM can also be used as a donor for Cy5. The length of the spacing between each donorlacceptor pair can be changed systematically to achieve the expected fluorescence signatures as shown in Table 1. FAM and TAM can be introduced using 25 phosphoramidite FAM-dT and TAM-dT and Cy5 can be introduced to the modified T carrying an amino linker as described above. The use of such spacers is advantageous in several aspects: (i) the spacer will not hybridize to any sequences within the DNA
30 template and therefore false priming is avoided; (ii) the linkage of the spacer maintains the natural nucleic acid phosphate functionality, which avoids possible anomalies in electrophoretic mobility; and (iii) the elimination of the aromatic base groups on the deoxyribose rings in the spacer may reduce the likelihood of fluorescence quenching.
The second synthetic approach requires sophisticated selective synthetic chemistry procedures for the CFET
tag construction. As an example, Figure 3B shows a general scheme for the construction of CFET-deoxyuridine triphosphate (dUTP) using poly-proline (P) peptide as a spacer. The spacing between each donor/acceptor pair can be changed systematically to achieve the expected fluorescence signatures as shown in Table 1. Figure 4 shows a scheme for the synthesis of CFET-dUTP consisting of Fam, Tam and Cy5. Peptide synthesis procedure using tert-butylcarbonyl (t-Boc) chemistry is employed on a peptide synthesizer to construct the scaffold of the desired molecules. Starting with a glycine-resin as C-terminal, a modified proline tagged with FAM (Fam-proline) is coupled to glycine, then proline monomers are added, followed by reacting with another modified proline that has a protected primary amino linker (TFA-NH-proline) for the subsequent incorporation of Tam. Next, proline spacer is again added, followed by reacting with the azido-proline for the subsequent incorporation of CyS. After cleavage from the resin and removal of the trifluoroacetyl group, compound 1 in Figure 4 is obtained. Compound 1 reacts with TAM-NHS ester to form compound 2, which will then react with Cy5-phosphine (3) to produce compound 4, which has all the three dyes incorporated. Cy5-phosphine (3) can be synthesized using the modified Staudinger reaction developed by Bertozzi (Saxon and Bertozzi, 2000). Conversion of compound 4 to an NHS ester produces 5, which is then coupled to Aminoallyl (AA)-dUTP (Sigma) to generate the final product CFET-dUTP.
By varying the number of proline spacers between Fam and Tam, and between Tam and Cy5, a library of CFET-dUTPs with unique fluorescence signatures can be developed. The intermediates 2, 4, 5, and the final products can be purified by high pressure liquid chromatography (HPLC), size exclusion chromatography and gel electrophoresis.. The structures of AA-dUTP, Fam-Proline, and NHS esters of TAM and Cy5 are shown in Figure 5. Brief synthetic schemes for the synthesis of trifluoroacetic (TFA) - NH-proline, Fam-proline, azido-proline and Cy5-phosphine are shown in Figure 6. Unique fluorescence signatures for 8 synthesized CFET tags are shown in Figure 7.
II. Biomedical Applications of Combsnatora.al Fluorescence Energy Transfer Tags The ability to sequence DNA accurately and rapidly is revolutionizing biology and medicine. The confluence of the massive Human Genome Project is driving an exponential growth in the development of high throughput genetic analysis technologies. This rapid technological development involving biology, chemistry, computer science, and engineering makes it possible to move from studying genes one by one to approaches which can analyze and compare entire genomes.
Sophisticated techniques have enabled large-scale dissection of genomes. For instance, the development of cloning vectors which can maintain and reproduce large stretches of DNA (up to a million bases) has resulted in clone libraries which span most of the chromosomes from end to end for many of the highly S studied organisms including humans - so-called physical maps. Recognizing sequence markers that differ from one individual to another across the human genome has permitted them to be followed in families that harbor genetic diseases. If a marker cosegregates with the disease phenotype, one can be assured that the marker is in the vicinity of the gene responsible for that disease. Automated sequencing methods have made it possible to obtain the complete chemical composition of the genome with unprecedented speed, and computational approaches axe beginning to allow annotation of these sequences, identification of the genes and other elements that comprise the chromosomes. Gene expression has moved from the arena of analyzing a few genes at a time by the techniques of Northern blot analysis, to creating vast microarrays of these genes on glass slides or silicon chips (Schena et al. 1995, Chee et al. 1996).
Methods for identifying single nucleotide polymorphisms (SNPs) (Chen and Kwok, 1997), DNA-protein and protein-protein interactions (Uetz et al.
2000), and members of metabolic, signal transduction and other pathways are also being developed. All these advances will have the potential to revolutionize medical and clinical research in establishing diagnostic, prognostic or treatment options.
It is noteworthy that many of the genomic techniques mentioned have benefited from the use of novel molecular tags, especially fluorescent dye molecules.
DNA sequencing serves as a good example for evaluating the impact of this technology. Although the ability to obtain DNA sequences originated in the late 1970's with the development of the chemical cleavage approach of Maxam and Gilbert (1977) and the dideoxynucleotide terminator approach of Sanger et al . ( 1977 ) , it was the latter that was most amenable to automation and fluorescent labeling strategies.
In the past 15 years, in rapid succession, the ability to use four dyes in a single sequencing lane, one for each of the four bases in DNA (Smith et al.
1986), the ability to use cycle sequencing with heat stable enzymes (Tabor et al. 1995), the development of energy transfer dyes which produced higher signals (Ju et al., 1995; Lee et al., 1997), and mare recently, the ability to obtain long sequence reads in separate capillary tubes instead of adjacent lanes on polyacrylamide slab gels, has made sequencing increasingly robust. Future improvements in sequencing technology, including miniaturization and solid phase approaches, will continue to take advantage of energy transfer (ET) and other novel fluorescent tags (Ju et al., 1997). Investigators are also utilizing ET dyes for investigating gene expression on microarrays (Hacia et al. 1998). All of these approaches are believed to be limited to single pairs of donor and acceptor dyes for each reaction. The CFET approach described herein whereby one, two or more dyes, disposed at varying molecular distances from each other to generate many alternative discrete signatures offers the possibility of obtaining an order of magnitude higher throughput in many of these genomic approaches.
Genetic mutation and chromosome analysis are two 5 examples of the biomedical application of these CFET
tags. Using CFET tags in combination with single fluorophore tags, and/or multiple dye tags where no FET occurs, the number of possible unique fluorescence signatures, and hence the number of e.g.
10 SNPs detectable simultaneously, is hugely increased.
Gene mutations play important roles in the development of many human diseases. It has become increasingly apparent that missense mutations (single 15 base changes usually culminating in amino acid changes or introduction of stop codons which lead to truncated proteins), microdeletions and microinsertions (both of which can change the reading frame and also usually lead to protein truncation) 20 can occur at many positions along the length of the responsible gene. A number of studies have sought to identify causative mutations and predisposing polymorphisms for a number of cancers and other diseases. These include chronic lymphocytic leukemia 25 and other blood cancers (Kalachikov et al. 1997; Qu et al. 1998), the long QT syndrome (an ionic disturbance in the heart visible on electrocardiograms and an important risk factor for sudden cardiac death), breast cancer (Fischer et al.
30 1996), the rare ICF syndrome (immune deficiency/centromeric instabilitylfacial anomalies) (Xu et al. 1999), and more recently such complex disorders such as asthma and diabetes.
With the exception of the types of small mutations described above and single nucleotide polymorphisms that occur, on average, every 1000 nucleotides, the 6 billion nucleotide pairs that make up the diploid human genome are largely identical from individual to individual. Nonetheless, large deletions, amplifications and rearrangements do occur, and such chromosomal anomalies are often associated with serious and life-threatening diseases. The best known example is probably the third copy of chromosome 21 in individuals with Down syndrome, bu many other chromosomal translocations and macrodeletions are associated with cancer and other disease syndromes. If one is able to mark the positions along chromosomes with identifiable "color-coded" probes, it should be possible to easily detect such large-scale changes in chromosomal geography.
In fact, the field of chromosome painting (multicolor fluorescence in situ hybridization (M-FISH) has been used for just such analyses (Speicher et al. 1996). A
larger set of more readily separable CFET tag signatures might greatly aid in this enterprise. The established chromosome painting techniques require appropriate mixing of the different dyes prior to labeling, and so are used almost exclusively for labeling whole chromosomes.
III. CFET Tags for Multiplex Gene Mutation Detection Using I~igase Chain Reaction Ligase chain reaction (ZCR) is a procedure for genetic mutation analysis using ligase and a pair of oligonucleotides (Eggerding, 1995; Wu and Wallace, 1989; Landegren et al., 1988). Briefly, it is based on the fact that two adjacent oligonucleotides can only be ligated if the adjoining bases are complementary to the template strand. If there is a single base difference within two bases of the join site, ligation will not occur. Pairs of oligonucleotides are designed spanning the ligation site on the template DNA, including one harboring either the wild-type or mutated base. In the usual procedure, one of the oligonucleotides is radiolabeled at the phosphate group at its 5' end.
Following the ligase chain reaction, which involves multiple rounds of denaturing, primer annealing and ligation, one can separate the products from the substrates on polyacrylamide gels. The procedure can be modified using single stranded DNA template as shown in Figure 8 for testing using the CFET tags.
Primer pairs are generated surrounding a base that can be mutated. For example, the template may contain a T wild-type, wt) or C (mutated, mut) at the relevant position. The wt primers are complementary to the wt template at every position.
The primer on the right side of Figure 8A is labeled with CFET tag 1 to yield a specific fluorescent signature.. The mutation-specific primer, two bases longer than its wild-type analog, is complementary to every position of the mutated template. This primer is labeled with CFET tag 2 displaying another unique fluorescent signature. A common 20 base pair primer will be used on the other side of the ligation site .
In cases where ligation does not occur, because a wild-type oligonucleotide was used with a mutated template sequence, or a mutated oligonucleotide was used with a wild-type template sequence, the only fluorescent band on the acrylamide gel will be the size of the tagged primer. In contrast, if there is no mismatch at the ligation junction, two fluorescent bands, one the size of the primer and one the size of the joined primers will form. Following ligase chain reaction, the left and right primer will be ligated only if they are completely complementary to the 1p template. Thus, with a wt template, only a 40 base product will result, and only a 42 base product will result from a mut template as shown in Figure 8B. By virtue of the unique fluorescence emission signatures of the CFET tags, it is possible to display the products of several mutation positions simultaneously, each labeled with a different CFET
Tag. The ligated products can be separated and analyzed in a single gel lane. In order to accomplish this, the multiplex set of oligonucleotides that contain the potentially mutated position can be 5'-end labeled, each with a specific CFET tag. For example, one can test four different mutation sites using eight distinct CFET tags.
As shown in Table 2, eight primers labeled with eight unique CFET tags (1, 2, 3, 4, 5, 6, 9, and 10 of Table 1) can be constructed as shown in the general labeling scheme in Figure 3A using 1',2'-dideoxysugar phosphate (S) as spacers. For this set of CFET tag constructs, FAM is used as a common donor, and TAM
and/or Cy5 as acceptors. The length of the spacing between each donor/acceptor pair, (S)m and (S)n, can be changed systematically to achieve the expected fluorescence signatures as depicted in Table 1. FAM
and TAM can be introduced using FAM-dT and TAM-dT
phosphoramidites and Cy5 can be introduced to the modified T carrying an amino linker as described above.
The system can be tested, for example, by synthesizing single stranded DNA templates mimicking known single base mutations in exon 20 of the retinoblastoma susceptibility (RB1) gene (Schubert et al. 1994, Lohmann 1999). The sequences of two sets of synthetic templates (wt and mut) which can be used in the analysis are shown in Table 3. The sequence of the potential mutation positions is shown in bold-face as "A', "C", "G" and "T". Primer sets 1 and 2 in Table 2 are used for the testing of both wild type and mutated base positions of Template A, respectively while primer sets 3 and 4 are for testing both wild type and mutated base positions of Template B, respectively. To maximize the number of samples that can be detected on a polyacrylamide gel, the primers surrounding each "mutated" position can be designed to be a unique length as shown in Figure 9. For example, the two CFET labeled oligonucleotides (one for the wild-type gene and one for the mutated gene) surrounding mutation position 1 are 20 and 22 bases long, respectively, and the unlabeled common primer is 20 bases long. Any resulting ligation product will be either 40 or 42 bases long.
Likewise, for mutation position 2, 24 and 26 base labeled oligonucleotides can be constructed, as well as a different 20 base common primer, leading to ligation products of either 44 or 46 bases. More primers can, of course, be generated by making the sizing increment one base instead of two bases for each different mutation, or creating a second set of labeled primers whose ligation products run between 5 80 and 98 base pairs, between 120 and 138 base pairs, etc. Since single base pair resolution up to the length of ~ 400 by DNA fragments is easily achieved in polyacrylamide gel electrophoresis, the ligated products can be readily resolved in such standard 10 fluorescent gel systems. Furthermore, the advantage of being able to clearly distinguish the products based on their fluorescent signatures, as well as size, makes this assay extremely powerful. Expected gel electrophoresis results for this multiplex 15 testing system are shown on the right side of Figure 9. Here, template collection 1 is seen to contain only wt sequences. In contrast, template pool 2 contains one template with a mutation at position 2 and a heterozygote genotype at position 4.
Table 2. Eight primers used for multiplex mutation rlci-cri-i nn Primer 1L: 3'-ttaaaaagaataagggtgtc-5' (SEQ ID N0: 2) Primer 1R wt: 3'-Acatagccgatcggatagag-5'-CFET1 (SEQ ID N0: 3) Primer 1R mut: 3'-Tcatagccgatcggatagaggc-5'-CFET2 (SEQ ID N0: 4) Primer 2L: 3'-acatagccgatcggatagag-5' (SEQ ID NO: 5) Primer 2R wt: 3'-Gccgatttatgtgaaacacttgcg-5'-CFET3 ( SEQ I D NO : 6 ) Primer 2R mut: 3'-Accgatttatgtgaaacacttgcgga-5'-CFET4 (SEQ ID N0: 7) Primer 3L: 3'-cggaagacagactcgtgggt-5' (SEQ ID N0: 8) Primer 3R wt: 3'-Cttaatcttgtatagtagacctgggaaa-5'-CFET5 (SEQ ID N0: 9) Primer 3R mut: 3'-Attaatcttgtatagtagacctgggaaaag-5'-CFET6 (SEQ ID N0: 10) Primer 4L: 3'-atagtagacctgggaaaagg-5' (SEQ ID NO: 11) Primer 4R wt: 3''-Tcgtgtgggacgtcttactcatacttgagt-5'-CFET9 (SEQ ID NO: 12) Primer 4R mut: 3'-Gcgtgtgggacgtcttactcatacttgagtac-5'CFET10 (SEQ ID N0: 13) Table 3. The sequence of the two sets of synthetic templates (wt and mut) Template A:
5'-gtaaaaatgactaatttttcttattcccacagTgtatcggctagcctatc tcCggctaaatacactttgtgaacgccttctgtctgagcacccagaatta-3' (wild type) (SEQ ID N0: 14) 5'-gtaaaaatgactaatttttcttattcccacagAgtatcggctagcctatc tcTggctaaatacactttgtgaacgccttctgtctgagcacccagaatta-3' (mutated) (SEQ ID NO: 15) Tem late B:
5'-tacactttgtgaacgccttctgtctgagcacccaGaattagaacatatca tctggacccttttccAgcacaccctgcagaatgagtatgaactcatgaga-3' (wild type) (SEQ ID NO: 16) 5'-tacactttgtgaacgccttctgtctgagcacccaTaattagaacatatca tctggacccttttccCgcacaccctgcagaatgagtatgaactcatgaga-3' (mutated) (SEQ ID NO: 17) IV. CfET Tag Labeled Probes for Chromosome-wide Analysis Probes can be generated using a random primed labeling method to incorporate CFET-dUTP into chromosome-specific DNA molecules or cosmids disposed along the length of a given chromosome. Metaphase spreads of fresh cells or deparaffinized material can be prepared by standard methodologies, and the tagged probes can be hybridized to the chromosomes. Bulky ET dyes consisting of two individual fluorescent molecules, as well as dyes with a long linker, have been attached to deoxynucleotides (dNTPs) and dideoxynucleotides (ddNTPs) which have been shown to be good substrates for DNA polymerase (Rosenblum et al. 1997, Zhu et al. 1994). Thus, the CFET-dUTP
should be able to be incorporated into the growing strand by the polymerase reaction. In the actual random priming reaction, the ratio of regular deoxythymine triphosphate (dTTP) and CFET-dUTP can be adjusted, so that only a small portion of CFET-dUTP
will be incorporated into the growing chain, just enough to be detected by the optical method.
Numerical and structural chromosome rearrangements are a major cause of human mortality and, morbidity.
Aneuploidy of whole chromosomes accounts for at least 500 of early embryonic lethality, and also leads to severe patterns of congenital malformation such as Down syndrome. Segmental aneuploidies due to deletions and duplications also lead to malformation syndromes, as well as being associated with many types of cancer.
Traditional cytogenetic analysis is hampered by problems of resolution and interpretation inherent in standard banding analysis. In the last decade the use of fluorescent labeled DNA probes on chromosome preparations as well as on interphase nuclei has greatly improved the resolution and accuracy of cytogenetic diagnosis. Microdeletions and amplifications too small to be visible under the light microscope by banding can now be visualized using chromosome and region specific fluorescently labeled probes. Multiplexing this system is possible using combinations of probes labeled with different fluors. Sets of up to five differently labeled probes have been used for diagnostic purposes on interphase nuclei to determine aneuploidy in prenatal samples (Munne et al. 1998). M-FISH and Spectral Karyotyping use a combinatorial approach of five dyes to "paint"
all 23 pairs of human chromosomes so they can be distinguished using computerized image software (Schrock et al. 1996, Speicher et al. 1996).
However, these established techniques require careful mixing of dyes in controlled ratios. Quality control is often a problem, and the commercially available probes are very expensive.
CFET Tags are expected to have a substantial advantage over currently available dye sets. It should be possible to generate a larger number of CFET tag sets, reducing the need for a combinatorial approach. Quality control is also likely to be easier, since each probe needs to be labeled with only one tag, and probe sets can be mixed in equal quantities to produce multicolor FISH reagents.
5 CFET Tags for example could be used both for the detection of aneuploidy in interphase nuclei, and for the detection of submicroscopic chromosomal deletions and amplifications. For aneuploidy detection, for example, a set of eight different CFET tag labeled 10 probes can be prepared, each specific for one of the chromosomes most commonly involved in aneuploidy in either embryonic losses or birth defects (chromosomes 13, 15, 16, 18, 21, 22, X and Y) .
15 A schematic of a procedure for comprehensive chromosome-wide analysis for gain or loss of genetic material is shown in Figure 10. In the example, eight probes each labeled with a CFET-dUTP that emits a unique fluorescence signature are hybridized along 20 a chromosome in eight separate locations. The normal chromosome A will display eight unique fluorescence signatures of each probe in a defined order. A loss of fluorescence signature "2" in chromosome B will indicate the deletion of the complementary sequence 25 of probe 2. Whereas, in chromosome C, the appearance of two signatures of "3" will indicate the expansion of the complementary sequences for probe 3.
Standard sets of cosmid and BisAcryloylCystamine 30 (BAC) markers at 2-3 Mb intervals along the chromosomes are being developed in several laboratories, including a National Cancer Institute sponsored project, the Cancer Chromosome Aberration Project (CCAP: webpage ::~.,~~: . ncbi . nlm. nih . ~oTa/nci~.::~,ao,r j . Sets of differentially CFET-labeled ordered probes specific for particular chromosomal regions can be prepared.
Using FISH, one can then determine the limits of suspected or known deletions.
V. Use of CFET Tags In Other Multi-Component Analyses The CFET tags with unique fluorescence signatures which are disclosed in the present application will have utility in other applications involving multi component analysis in addition to those disclosed above. Additional applications include, but are not limited to, multiplex assays including binding assays and immuno assays, detection of microbial pathogens, monitoring multiple biomolecular reactions, screening of drugs or compounds, epitope mapping, allergy screening, and use with organic compounds and in material science. For example, multiple reactions or interactions can be measured simultaneously, where multiple CFET tags, each with a different fluorescence signature, are used to label the different reactants which could include, for example, antibodies, antigens, ligands, or substrates.
Examples include antibody-antigen and receptor-ligand binding. In further examples, different reactants can be coupled to microspheres.
VI. CFET Tags Used in Ligation Assay to Identify Multiple Single Nucleotide Polymorphisms.
As an example of application for biological assays, the CFET tags were applied to an oligonucleotide ligation assay (Zandegren, 1988) coupled with solid phase purification to detect genetic mutations on exon 20 of the tumor suppressor retinoblastoma (RB1) gene. The schematic of the approach is shown in Fig.
11. Two 20 base-pair oligonucleotides, one labeled with a CFET tag at the 5' end and the other labeled with a biotin at the 3' end and a monophosphate (P) group at the 5' end, are hybridized to the target DNA
template such that the 3' end of the CFET-labeled oligonucleotide is positioned next to the 5' end of the biotinylated oligonucleotide. Taq DNA lipase joins the two juxtaposed oligonucleotides in a head-to-tail fashion by forming a phosphodiester bond, provided that the nucleotides at the ligating junction of the two oligonucleotides are correctly base-paired with the template (Barany, 1991). Under the experimental conditions using Taq DNA lipase, no ligation reaction occurs when there is a mismatch between the 3' end of the CFET-labeled probe (nucleotides A and C, Fig. 11) and the SNP site (nucleotides T and G, Fig. 11) on the target template. After the ligation, the CFET-labeled ligation products (40 base-pair) are immobilized to streptavidin-coated magnetic beads while the other components are washed away. The ligation products are then cleaved from the magnetic beads by denaturing the biotin-streptavidin interaction with formamide and analyzed with a three-color fluorescence CAE
system. The CFET-labeled ligation products are unambiguously detected due to their distinct mobility and unique fluorescence signatures in the electropherogram, see Figure 12. In the case of heterozygotes at the SNP site, two CFET tags with different fluorescence signature and electrophoretic mobility are used to label the oligonucleotides corresponding to each allele. The unique fluorescence signatures in the electropherogram thus identify each of the corresponding SNPs. The solid phase procedure completely eliminates the unligated CFET-labeled oligonucleotide. Although the unligated 20 base-pair biotinylated oligonucleotides are also captured by the magnetic beads, they do not produce fluorescence signals due to the absence of CFET tags. The CFET tag library in this application detects multiple SNPs on the target DNA template simultaneously.
Exon 20 of the tumor suppressor RB1 gene (Schubert, 1994) was selected as a model system to test the utility of the CFET tags. Several SNPs within a region of 200 base pairs in the RB1 gene have been found, which are well suited for evaluating a genetic mutation analysis system. Six ligation reactions were carried out separately using six different CFET tags on synthetic templates mimicking exon 20 of the RB1 gene where multiple SNPs (six nucleotide variations) are located. After the ligation and solid phase purification, the ligation products were combined in a single tube and analyzed with a three-color CAE
system, resulting in the simultaneous detection of six nucleotide variations by the unique fluorescence signatures of the CFET-labeled ligation products (see Figure 12A). The unique fluorescence signatures were spatially resolved in the electropherogram as a result of the different mobility of the CFET-labeled ligation products. In this model experiment, both CFET-1 (FAM) and CFET-6 (F-10-Cy5) detect homozygous SNPs (T/T). CFET-3 (F-9-T) and CFET-4 (F-13-T) clearly distinguish a mimic of RB1 gene mutation R661W (amino acid change from arginine to tryptophan due to mutation in codon 661) by detecting both the wild type (C) and~the mutation (T). CFET-7 (F-4-T-6-Cy5) and CFET-8 (F-7-T-7-Cy5) identify another mutation Q685P (amino acid change from glutamine to proline due to mutation in codon 685) with heterozygous genotype (A/C). To validate the CFET
technology further used three CFET-labeled oligonucleotide probes (CFET-1, 3 and 7) and their corresponding biotinylated oligonucleotides to identify three SNPs using a PCR product amplified from exon 20 of the RB1 gene from patient genomic DNA. The ligation reactions were performed in a single tube and the reaction products were loaded onto a three-color CAE system. Three individual homozygous SNPs (T, C and A), that were verified by DNA sequencing, were unambiguously identified by the three distinct fluorescence signatures from the CFET
tags (figure 12B): T (FAM, CFET-1), C (F-9-T, CFET-3) and A (F-4-T-6-Cy5, CFET-7). Thus, the approach described here can detect both heterozygotes and homozygotes unambiguously because of the unique CFET
fluorescence signature and mobility in the electropherogram.
To increase the level of control available in isolation other isolation-permitting moieties besides biotin may be employed such as phenylboronic acid.
Attachment of the moieties via cleavable linker S molecules enhances this still further.
VII. CFET Tags Used in Single Base Primer Extension to Identify Multiple Single Nucleotide Polymorphisms.
10 Single base extension for each dye-labeled primer was done by mixing 0.5 to 1 pmol of the primers with 1 pmol of template, followed by adding 2 u1 of thermo sequenase lOX reaction buffer (260 mM Tris-HCl, 65 mM
MgCl2, pH 9.5, Amersham Pharmacia Biotech, Piscataway, 15 NJ), 5 u1 of water, 1 pmol of biotinylated dideoxynucleoside triphosphates (Biotin-11-ddNTP, NEN, Boston, MA) and 1 unit of thermo sequenase in 20 mM Tris-HC1, pH 8.5, 50o glycerol, 0.1 mM
ethylenediamine tetraacetic acid (EDTA), 0.5% TweenTM_ 20 20 (v/v), 0.5o NonidetTM P-40 (v/v), 1mM
dithiothreitol (DTT), 100 mM KC1 and 0.053 unit/ul Thermoplasma acidophilum inorganic pyrophosphatase (Amersham Pharmacia Biotech). The reaction mixture was incubated at 54°C for 30 sec for single base 25 extension.
Schematic representation of the multiplex SNPs detection using CFET tags and biotinylated dideoxynucleotides is shown. in Figure 13. In this 30 example, extension of the primers are initiated by ddCTP-Biotin (for primer 1) and ddGTP-Biotin (for primer 2) in the presence of DNA polymerase if there is a match between the 3' end of the primer and the template (X and Y for primer 1; X' and Y' for primer 2). The extension products are isolated using streptavidin-coated magnetic beads. Upon denaturing, washing and releasing from the beads, the extension products are loaded onto an electrophoresis system and the resulting fluorescence signatures from the electropherogram identify each of the unique SNPs.
Thus, the CFET-labeled oligonucleotides, DNA
polymerase and biotinylated dideoxynucleotides form a high fidelity SNP detection system in which the base at the 3' end of the oligonucleotides dictates its extension by incorporating a specific biotinylated dideoxynucleotide. The CFET tags used were F, ~F-9-T.
and F-13-T. Their unique fluorescence signatures are shown in Figures 14 and 15 To increase the level of control over isolation, other isolation-permitting moieties such as phenylboronic acid, antigens or antibodies may be employed in place of the biotin. Attachment of the moieties via cleavable linker molecules enhances this still further.
VIII. High Throughput Analyses.
The throughput of the multiplex analyses offered by the use of the CFET tags can be increased by performing the analyses in the high throughput chamber illustrated in figure 16.
IX. In combination with non-FET tags.
To increase the number of different unique fluorescent signatures available in any set of tags CFET tags can be used in combination with single chromophore/fluorophore tags and tags with multiple chromophores/fluorophores where no FET occurs. The number of possible different fluorescence signatures using such combinations is huge, and would greatly aid multiplex analyses. Such fluorophores could be quantum dots, luminescent molecules of fluorescent dyes. For example, each tag could be used to detect a different SNP using the exemplified assays.
References U.S. Patent No. 6,028,190 issued February 222, 2000, Mathies et al.
Barany, F. (1991) Genetic disease detection and DNA
amplification using cloned thermostable ligase. PNAS.
88:189-193.
Benson, S. C., Mathies, R. A. & Glazer, A. N. (1993).
Heterodimeric DNA-binding dyes designed for energy transfer: stability and applications of the DNA
complexes. Nucleic Acids Res. 21: 5720-5726.
Benson, S. C., Singh, P. & Glazer, A. N. (1993).
Heterodimeric DNA-binding dyes designed for energy transfer: synthesis and spectroscopic properties.
Nucleic Acids Res. 21: 5727-5735.
Chee, M., Yang, R., Hubbell, E., Berno, A., Huang, X.
C., Stern, D., Winkler, J., Lockhart, D. J., Morris, M. S., Fodor, S. P. (1996). Accessing genetic information with high-density DNA arrays. Science.
274:610-614.
Chen, X. and Kwok, PY. (1997) Template-directed dye-terminator incorporation (TDI) assay: a homogeneous DNA diagnostic method based on fluorescence resonance energy transfer Nucl. Acids. Res. 25: 347-353.
Eggerding FA (1995) A one-step coupled amplification and oligonucleotide ligation procedure for multiplex genetic typing. PCR Methods Appl. 4: 337-345.
Fischer, S.G., Cayanais, E., de Fatima Bonaldo, M., Bowcock, A.M., Deaven, L.L., Edelman, I.S., Gallardo, T., Kalachikov, S., Lawton, L., Longmire, J.L., Lovett, M., Osborne-Lawrence, S., Rothstein, R., Russo, J.J., Soares, M.B., Sunjevaric, I., Venkatraj, V.S., Warburton, D., Zhang, P. and Efstratiadis, A.
(1996) A high-resolution annotated physical map of the human chromosome 13q12-13 region containing the breast cancer susceptibility locus BRCA2. Proc.
Natl. Acad. Sci. U.S.A. 93: 690-694.
Forster, T. (1965) In: Modern quantum Chemistry, Istanbul Lectures, Part III. Sinanoglu, O. (editor), Academic Press, New York, pp 93-137.
Glazer, A.N., Stryer, L. (1983) Fluorescent tandem phycobiliprotein conjugates. Emission wavelength shifting by energy transfer. Biophys. J. 43(3):383 386.
Hacia J.G., Edgemon K., Sun B., Stern D., Fodor S.A., Collins F.S. (1998). Two Color Hybridization Analysis Using High Density Oligonuleotide Arrays and Energy Transfer Dyes Nucleic Acids Research 15; 26: 3865-6 Ju, J., Glazer, A.N. & Mathies, R.A. (1996) Cassette labeling for facile construction of energy transfer fluorescent primers. Nucleic Acids Res. 24, 1144 1148.
Ju J, Glazer AN and Mathies RA (1996) Energy transfer primers: A new fluorescence labeling paradigm for DNA
sequencing and analysis. Nature Medicine 2: 246-249.
5 Ju J, Ruan C, Fuller CW, Glazer AN and Mathies RA
(1995) Energy transfer fluorescent dye-labeled primers for DNA sequencing and analysis. Proc. Natl.
Acad. Sci. USA 92: 4347-4351.
10 Ju J, Yan H, Zaro M, Doctolero M, Goralski T, Konrad K, Lachenmeier E and Cathcart R (1997) DNA sequencing with solid phase captureable terminators. Microb.
Comp. Genomics 2: 223.
15 Kalachikov, S. et al. (1997) Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics 42(3): 369-377.
Landegren U, Kaiser R, Sanders J and Hood L (1988) A
20 ligase-mediated gene detection technique. Science 241: 1077-1080.
Lee LG, Spurgeon SL, Heiner CR, Benson SC, Rosenblum BB, Menchen SM, Graham RJ, Constantinescu A, Upadhya 25 KG and Cassel JM (1997) New energy transfer dyes for DNA sequencing. Nucleic Acids Res. 25: 2816-2822.
Lohmann DR (1999) RB1 gene mutations in retinoblastoma. Hum Mutat. 14: 283-288 Maxam AM and Gilbert W (1977) A new method for sequencing DNA. Proc Natl. Acad. Sci. USA 74: 560-564.
Munne S, Magli C, Bahce M, Fung J, Legator M, Morrison L, Cohert J, Gianaroli. (1998) Preimplantation diagnosis of the aneuploidies most commonly found in spontaneous abortions and live births: XY, 13, 14, 15, 16, 18, 21, 22. Prenat Diagn.
18: 1459-66.
Qu, X., Hauptschein, R.S., Rzhetsky, A., Scotto, L., Chien, M., Ye, X., Frigeri, F., Rao, P.H., Pasqualucci, L., Gamberi, B., Zhang, P., Chaganti, R.S.K., Dalla-Favera, R. and Russo, J.J. (1998) Analysis of a 69 kb contiguous genomic sequence at a putative tumor suppressor gene locus on human chromosome 6q27. DNA Seq. 9: 189-204.
Rosenblum, B.B., Lee, L.G., Spurgeon, S.L., Khan, S.H., Menchen, S.M., Heiner, C.R., Chen, S.M.(1997).
New dye-labeled terminators for improved DNA
sequencing patterns. Nucleic Acids Res 25: 4500-4 Rye, H. S., Drees, B. L., Nelson, H. C. M. & Glazer, A. N. (1993). Stable fluorescent dye-DNA complexes in high sensitivity detection of protein-DNA
interactions. Application to heat shock transcription factor. J. Biol. Chem. 268: 25229-25238.
Sambrook et al., "Molecular Cloning: A Laboratory Manual", Second Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
Sanger F, Nickeln S and Coulson AR (1977) DNA
sequencing with chain-terminating inhibitors. Proc.
Natl. Acad. Sci. USA 74: 5463-5467.
Saxon E and Bertozzi CR (2000), Cell Surface Engineering by a Modified Staudinger Reaction.
Science, 287; 2007-2010.
Schena, M., Shalon D., Davis, R. and Brown P.~.
(1995) Quantitative monitoring of gene expression patterns with a cDNA microarray. Science 270:467-470.
Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Yand Ried T (1996) Multicolor spectral karyotyping of human chromosomes.
Science 273: 494-497.
Schubert EL, Hansen MF and Strong LC (1994). The retinoblastoma gene and its significance. Ann Med.
26: 177-184.
Smith, L. M., Sanders, J.2., Kaiser, R. J., Hughes, P., Dodd, C., Connell, C. R., Heiner, C., Kent, S.B.H. and Hood, L. E. (1986). Fluorescence detection in automated DNA sequencing analysis. Nature. 321:
674-679.
Speicher MR, Ballard SG and Ward DC (1996) Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genet. 12: 368-375.
Stryer, L. (1978) Fluorescence energy transfer as a spectroscopic ruler. Annu. Rev. Biochem. 47: 819-846.
Tabor, S. & Richardson, C. C. A single residue in DNA
polymerases of the Escherichia coli DNA polymerase I
family is critical for distinguishing between deoxy-and dideoxyribonucleotides. 1995. Proc. Natl. Acad.
Sci. U.S.A. 92: 6339-6343.
Uetz, et al; and S. Fields (2000) A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 403 (Number 6770) 623 - 627.
Vogel. (1989) Textbook Of Practical Organic Chemistry, Fifth Edition, Addison Wesley Longman, Harlow, U.K.
Wu DY and Wallace RB (1989) The ligation amplification reaction (LAR): Amplification of specific DNA sequences using sequential rounds of template-dependent ligation. Genomics 4: 560-569.
Xu, G-L. wt al. (1999) Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402: 187-191.
Zhu Z ; Chao J ; Yu H ; Waggoner AS ( 1994 ) . Directly labeled DNA probes using fluorescent nucleotides with different length linkers. Nucleic Acids Res, 22:
3418-22.
SEQUENCE LISTING
<110> Ju, Jingyue Russo, James J
Tong, Anthony Li, Zengmin <120> Combinatorial Fluoresence Energy Transfer Tags And Their Applications For Multiplex Biological Analyses <130> 0575/62238A/JPW/ADM
<140>
<141>
<150> 09/658,077 <151> 2000-09-11 <l60> 17 <170> Patentln Ver. 2.1 <210> 1 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: scaffold <400> l tttttttttt tttttttttt tttttc 26 <210> 2 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <900> 2 ttaaaaagaa taagggtgtc 20 <210> 3 <21I> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 3 acatagccga tcggatagag 20 <210> 4 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 4 tcatagccga tcggatagag gc 22 <210> 5 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 5 acatagccga tcggatagag 20 <210> 6 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <900> 6 gccgatttat gtgaaacact tgcg 24 <210> 7 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 7 accgatttat gtgaaacact tgcgga 26 <210> 8 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 8 cggaagacag actcgtgggt 20 <210> 9 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 9 cttaatcttg tatagtagac ctgggaaa 28 <210> 10 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 10 attaatcttg tatagtagac ctgggaaaag 30 <210> 11 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 1l atagtagacc tgggaaaagg 20 <210> 12 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 12 tcgtgtggga cgtcttactc atacttgagt 30 <210> 13 <211> 32 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <900> 13 gcgtgtggga cgtcttactc atacttgagt ac 32 <210> 14 <211> 100 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: template <400> 14 gtaaaaatga ctaatttttc ttattcccac agtgtatcgg ctagcctatc tccggctaaa 60 tacactttgt gaacgccttc tgtctgagca cccagaatta 100 <210> 15 <211> 100 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: template <400> 15 gtaaaaatga ctaatttttc ttattcccac agagtatcgg ctagcctatc tctggctaaa 60 tacactttgt gaacgccttc tgtctgagca cccagaatta 100 <210> 16 <211> 100 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: template <400> 16 tacactttgt gaacgccttc tgtctgagca cccagaatta gaacatatca tctggaccct 60 tttccagcac accctgcaga atgagtatga actcatgaga 100 <210> 17 <211> 100 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: template <400> 17 tacactttgt gaacgccttc tgtctgagca cccataatta gaacatatca tctggaccct 60 tttcccgcac accctgcaga atgagtatga actcatgaga 100
Claims (60)
1. A composition of matter comprising multiple fluorophores, each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer between one such fluorophore and another such fluorophore, wherein the one such fluorophore and the another such fluorophore are characterized by the maximum emission wavelength of one being greater than the minimum excitation wavelength of the other.
2. A composition of matter of claim 1 comprising two fluorophores, each of which is bound to a molecular scaffold, at a separate predetermined position on the scaffold, such separate positions being selected so as to permit fluorescence energy transfer between such fluorophores, and such fluorophores being characterized by the maximum emission wavelength of one of the fluorophores being greater than the minimum excitation wavelength of the other fluorophore.
3. A composition of matter of claim 1 comprising three fluorophores each of which is bound to a molecular scaffold at a separate predetermined position on the scaffold, such separate predetermined positions being selected so as to permit fluorescence energy transfer among such fluorophores and such fluorophores being characterized by the maximum emission wavelength of one such fluorophore being greater than the minimum excitation wavelength of the second such fluorophore and the maximum emission wavelength of such second fluorophore being greater than the minimum excitation wavelength of the third such fluorophore.
4. The composition of matter of the claim 1, wherein each fluorophore is covalently bound to the molecular scaffold.
5. The composition of claim 1, wherein the efficiency of the fluorescence energy transfer is less than 20%.
6. The composition of claim 1, wherein the molecular scaffold is rigid.
7. The composition of claim 1, wherein the molecular scaffold is polymeric.
8. The composition of claim 9, wherein the molecular scaffold comprises a nucleic acid.
9. The composition of claim 9, wherein the molecular scaffold comprises a peptide.
10. The composition of claim 9, wherein the molecular scaffold comprises as polyphosphate.
11. The composition of claim 1, wherein at least one fluorophore is a fluorescent dye.
12. The composition of claim 11, wherein the fluorescent dye is 6-carboxyfluorescein.
13. The composition of claim 11, wherein the fluorescent dye is N,N,N',N'-tetramethyl-6-carboxyrhodamine.
14. The composition of claim 11, wherein the fluorescent dye is cyanine-5 monofunctional dye.
15. The composition of claim 11, wherein at least one fluorophore is a luminescent molecule.
16. The composition of claim 11, wherein at least one fluorophore is a quantum dot.
17. A composition of matter having the structure:
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, each T represents a thymidine derivative, FAM represents 6-carboxyfluorescein derivative, TAM represents N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, each T represents a thymidine derivative, FAM represents 6-carboxyfluorescein derivative, TAM represents N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
18. The composition of claim 17, wherein m is 4.
19. The composition of claim 17, wherein m is 6.
20. The composition of claim 17, wherein m is 9.
21. The composition of claim 17, wherein m is 13.
22. A composition of matter having the structure:
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q are different.
23. The composition of claim 22, wherein m is 4.
24. The composition of claim 22, wherein m is 5.
25. The composition of claim 22, wherein m is 7.
26. The composition of claim 22, wherein m is 10.
27. The composition of claim 22, wherein m is 13.
28. A composition of matter comprising the structure shown below:
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, n is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q
are different.
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m is an integer greater than 1 and less than 100, n is an integer greater than 1 and less than 100, T represents a thymidine derivative, FAM represents a 6-carboxyfluorescein derivative, Cy5 represents a cyanine-5 monofunctional dye derivative, TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q
are different.
29. The composition of claim 28, wherein m is 3, and n is 7.
30. The composition of claim 28, wherein m is 4, and n is 6.
31. The composition of claim 28, wherein m is 5, and n is 5
32. The composition of claim 28, wherein m is 6, and n is 6.
33. The composition of claim 28, wherein m is 7, and n is 7.
34. A composition of matter comprising the structure shown below:
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m represents an integer greater than 1 and less than 100, T represents a thymidine derivative, and TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q
are different.
wherein S represents a 1',2'-dideoxyribose phosphate moiety, m represents an integer greater than 1 and less than 100, T represents a thymidine derivative, and TAM represents a N,N,N',N'-tetramethyl-6-carboxyrhodamine derivative, each solid line represents a covalent bond, R represents either a hydroxy or phosphate terminus and Q represents either a hydroxy or phosphate terminus, with the proviso that R and Q
are different.
35. The composition of claim 34, wherein m is 4.
36. A nucleic acid labeled with the composition of any of claims 1, 17, 22, 28 and 34.
37. The nucleic acid of claim 36, wherein the nucleic acid is DNA.
38. The nucleic acid of claim 36, wherein the nucleic acid is RNA.
39. The nucleic acid of claim 36, wherein the nucleic acid is DNA/RNA.
40. A method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:
contacting the nucleic acid, under hybridizing and DNA ligation-permitting conditions, with (i) a DNA ligase, (ii) a first oligonucleotide having affixed thereto a composition of matter of claim 1 wherein the first oligonucleotide hybridizes with nucleotides immediately adjacent one side of the predetermined position and (iii) a second oligonucleotide which hybridizes with the nucleotides immediately adjacent the other side of the predetermined position, wherein the hydroxy-terminal residue of the oligonucleotide which hybridizes to the nucleotide located 3' of the predetermined position is a nucleotide which is complementary to the preselected nucleotide residue; and (b) detecting the presence of a ligation product comprising both the first and the second oligonucleotides, the presence of such a ligation product indicating the presence of the preselected nucleotide residue at the predetermined position.
contacting the nucleic acid, under hybridizing and DNA ligation-permitting conditions, with (i) a DNA ligase, (ii) a first oligonucleotide having affixed thereto a composition of matter of claim 1 wherein the first oligonucleotide hybridizes with nucleotides immediately adjacent one side of the predetermined position and (iii) a second oligonucleotide which hybridizes with the nucleotides immediately adjacent the other side of the predetermined position, wherein the hydroxy-terminal residue of the oligonucleotide which hybridizes to the nucleotide located 3' of the predetermined position is a nucleotide which is complementary to the preselected nucleotide residue; and (b) detecting the presence of a ligation product comprising both the first and the second oligonucleotides, the presence of such a ligation product indicating the presence of the preselected nucleotide residue at the predetermined position.
41. A method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the method of
claim 42.
42. The method of claim 41, wherein the presence of a plurality of given nucleotide residues is determined simultaneously.
42. The method of claim 41, wherein the presence of a plurality of given nucleotide residues is determined simultaneously.
43. The method of claim 40, wherein the DNA ligase is Taq DNA ligase.
44. The method of claim 40, wherein the second oligonucleotide has an isolation-permitting moiety affixed thereto, and wherein the method further comprises the steps of isolating the moiety-containing molecules resulting from step (a) and determining the presence therein of ligated first and second oligonucleotides.
45. The method of claim 40, wherein the composition of matter affixed to the first oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of ligated first and second oligonucleotides in step (b).
46. A method of determining whether a preselected nucleotide residue is present at a predetermined position within a nucleic acid comprising the steps of:
(a) contacting the nucleic acid, under hybridizing and DNA polymerization-permitting conditions, with (i) a DNA
polymerase, (ii) an oligonucleotide (1) having affixed thereto a composition of matter of claim 1, and (2) having a hydroxyl 3' terminus thereof, wherein the oligonucleotide hybridizes with the 3' region of the nucleic acid molecule flanking the predetermined position, and (iii) a dideoxynucleotide labeled with an isolation-permitting moiety, wherein the labeled dideoxynucleotide is complementary to the given nucleotide residue, with the proviso that upon hybridization of the oligonucleotide with the nucleic acid in the presence of DNA polymerase and the preselected nucleotide residue, the oligonucleotide and dideoxynucleotide are juxtaposed so as to permit their covalent linkage by the DNA polymerase;
(b) detecting the presence of a polymerization product comprising both the oligonucleotide and the dideoxynucleotide, the presence of such a polymerization product indicating the presence of the preselected nucleotide residue at the predetermined position.
(a) contacting the nucleic acid, under hybridizing and DNA polymerization-permitting conditions, with (i) a DNA
polymerase, (ii) an oligonucleotide (1) having affixed thereto a composition of matter of claim 1, and (2) having a hydroxyl 3' terminus thereof, wherein the oligonucleotide hybridizes with the 3' region of the nucleic acid molecule flanking the predetermined position, and (iii) a dideoxynucleotide labeled with an isolation-permitting moiety, wherein the labeled dideoxynucleotide is complementary to the given nucleotide residue, with the proviso that upon hybridization of the oligonucleotide with the nucleic acid in the presence of DNA polymerase and the preselected nucleotide residue, the oligonucleotide and dideoxynucleotide are juxtaposed so as to permit their covalent linkage by the DNA polymerase;
(b) detecting the presence of a polymerization product comprising both the oligonucleotide and the dideoxynucleotide, the presence of such a polymerization product indicating the presence of the preselected nucleotide residue at the predetermined position.
47. A method of determining whether at various predetermined positions within a nucleic acid, a preselected nucleotide residue is present at such position, wherein the preselected nucleotide residue may vary at different predetermined positions which comprises determining whether each preselected nucleotide is present each predetermined position according to the method of claim 46.
48. The method of claim 46, wherein the DNA
polymerase is thermo sequenase.
polymerase is thermo sequenase.
49. The method of claim 46, wherein the dideoxynucleotide is selected from the group consisting of dideoxyadenosine triphosphate, dideoxycytidine triphosphate, dideoxyguanosine triphosphate, dideoxythymidine triphosphate, and dideoxyuridine triphosphate.
50. The method of claim 46, wherein the composition of matter affixed to the oligonucleotide has a predetermined emission spectrum, and wherein the observation of this emission spectrum is employed to determine the presence of polymerization product in step (b).
51. The method of claim 45 or 50, wherein observing the predetermined emission spectrum is performed using radiation having a wavelength of between 200 and 1000nm.
52. The method of claim 51, wherein the radiation has a wavelength of 488 nm.
53. The method of claim 45 or 50 wherein observing the predetermined emission spectrum is performed using radiation having a bandwidth of between 1 and 50nm.
54. The method of claim 53, wherein the radiation bandwidth is 1nm.
55. The method of claim 44 or 46, wherein the isolation-permitting moiety comprises biotin, streptavidin, phenylboronic acid, salicylhydroxamic acid, an antibody or an antigen.
56. The method of claim 55, wherein the isolation-permitting moiety is attached to the oligonucleotide via a linker molecule.
57. The method of claim 46, wherein the isolation-permitting moiety is attached to the dideoxynucleotide via a linker molecule.
58. The method of claim 56 or 57, wherein the linker molecule is chemically cleavable.
59. The method of claim 56 or 57, wherein the linker molecule is photocleavable.
60. The method of claim 59, wherein the linker molecule has the structure:
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/658,077 | 2000-09-11 | ||
US09/658,077 US6627748B1 (en) | 2000-09-11 | 2000-09-11 | Combinatorial fluorescence energy transfer tags and their applications for multiplex genetic analyses |
US30915601P | 2001-07-31 | 2001-07-31 | |
US60/309,156 | 2001-07-31 | ||
PCT/US2001/028967 WO2002022883A1 (en) | 2000-09-11 | 2001-09-11 | Combinatorial fluorescence energy transfer tags and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2421582A1 true CA2421582A1 (en) | 2002-03-21 |
Family
ID=26976642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002421582A Abandoned CA2421582A1 (en) | 2000-09-11 | 2001-09-11 | Combinatorial fluorescence energy transfer tags and uses thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1322785A4 (en) |
JP (1) | JP2004508838A (en) |
AU (1) | AU8911101A (en) |
CA (1) | CA2421582A1 (en) |
WO (1) | WO2002022883A1 (en) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6627748B1 (en) | 2000-09-11 | 2003-09-30 | The Trustees Of Columbia University In The City Of New York | Combinatorial fluorescence energy transfer tags and their applications for multiplex genetic analyses |
CA2425112C (en) | 2000-10-06 | 2011-09-27 | The Trustees Of Columbia University In The City Of New York | Massive parallel method for decoding dna and rna |
US9708358B2 (en) | 2000-10-06 | 2017-07-18 | The Trustees Of Columbia University In The City Of New York | Massive parallel method for decoding DNA and RNA |
US6942853B2 (en) * | 2001-01-09 | 2005-09-13 | Queen Mary And Westfield College | Latent fusion protein |
GB0129012D0 (en) | 2001-12-04 | 2002-01-23 | Solexa Ltd | Labelled nucleotides |
US7057026B2 (en) | 2001-12-04 | 2006-06-06 | Solexa Limited | Labelled nucleotides |
US7074597B2 (en) | 2002-07-12 | 2006-07-11 | The Trustees Of Columbia University In The City Of New York | Multiplex genotyping using solid phase capturable dideoxynucleotides and mass spectrometry |
US11008359B2 (en) | 2002-08-23 | 2021-05-18 | Illumina Cambridge Limited | Labelled nucleotides |
US7414116B2 (en) | 2002-08-23 | 2008-08-19 | Illumina Cambridge Limited | Labelled nucleotides |
EP3002289B1 (en) | 2002-08-23 | 2018-02-28 | Illumina Cambridge Limited | Modified nucleotides for polynucleotide sequencing |
WO2005084367A2 (en) | 2004-03-03 | 2005-09-15 | The Trustees Of Columbia University In The City Of New York | Photocleavable fluorescent nucleotides for dna sequencing on chip constructed by site-specific coupling chemistry |
US9040305B2 (en) | 2004-09-28 | 2015-05-26 | Singulex, Inc. | Method of analysis for determining a specific protein in blood samples using fluorescence spectrometry |
US8685711B2 (en) | 2004-09-28 | 2014-04-01 | Singulex, Inc. | Methods and compositions for highly sensitive detection of molecules |
US7060955B1 (en) * | 2005-01-31 | 2006-06-13 | Chemimage Corporation | Apparatus and method for defining illumination parameters of a sample |
US9169510B2 (en) | 2005-06-21 | 2015-10-27 | The Trustees Of Columbia University In The City Of New York | Pyrosequencing methods and related compositions |
GB2446083B (en) | 2005-10-31 | 2011-03-02 | Univ Columbia | Chemically cleavable 3'-0-allyl-dntp-allyl-fluorophore fluorescent nucleotide analogues and related methods |
US7982029B2 (en) | 2005-10-31 | 2011-07-19 | The Trustees Of Columbia University In The City Of New York | Synthesis of four color 3′O-allyl, modified photocleavable fluorescent nucleotides and related methods |
ES2703813T3 (en) * | 2006-04-04 | 2019-03-12 | Singulex Inc | Highly sensitive methods for the analysis of troponin |
EP1860197A1 (en) * | 2006-05-24 | 2007-11-28 | Humboldt-Universität zu Berlin | Method for detecting target nucleic acids using template catalyzed transfer reactions |
US8889348B2 (en) | 2006-06-07 | 2014-11-18 | The Trustees Of Columbia University In The City Of New York | DNA sequencing by nanopore using modified nucleotides |
US8399188B2 (en) | 2006-09-28 | 2013-03-19 | Illumina, Inc. | Compositions and methods for nucleotide sequencing |
US7883869B2 (en) | 2006-12-01 | 2011-02-08 | The Trustees Of Columbia University In The City Of New York | Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators |
GB0700640D0 (en) * | 2007-01-12 | 2007-02-21 | Iti Scotland Ltd | Detecting analytes |
WO2009051807A1 (en) | 2007-10-19 | 2009-04-23 | The Trustees Of Columbia University In The City Of New York | Design and synthesis of cleavable fluorescent nucleotides as reversible terminators for dna sequencing by synthesis |
US9115163B2 (en) | 2007-10-19 | 2015-08-25 | The Trustees Of Columbia University In The City Of New York | DNA sequence with non-fluorescent nucleotide reversible terminators and cleavable label modified nucleotide terminators |
US7914734B2 (en) | 2007-12-19 | 2011-03-29 | Singulex, Inc. | Scanning analyzer for single molecule detection and methods of use |
US8324914B2 (en) | 2010-02-08 | 2012-12-04 | Genia Technologies, Inc. | Systems and methods for characterizing a molecule |
US9605307B2 (en) | 2010-02-08 | 2017-03-28 | Genia Technologies, Inc. | Systems and methods for forming a nanopore in a lipid bilayer |
US9678055B2 (en) | 2010-02-08 | 2017-06-13 | Genia Technologies, Inc. | Methods for forming a nanopore in a lipid bilayer |
WO2012083249A2 (en) | 2010-12-17 | 2012-06-21 | The Trustees Of Columbia University In The City Of New York | Dna sequencing by synthesis using modified nucleotides and nanopore detection |
WO2012088339A2 (en) | 2010-12-22 | 2012-06-28 | Genia Technologies, Inc. | Nanopore-based single dna molecule characterization using speed bumps |
US9581563B2 (en) | 2011-01-24 | 2017-02-28 | Genia Technologies, Inc. | System for communicating information from an array of sensors |
US9110478B2 (en) | 2011-01-27 | 2015-08-18 | Genia Technologies, Inc. | Temperature regulation of measurement arrays |
WO2012162429A2 (en) | 2011-05-23 | 2012-11-29 | The Trustees Of Columbia University In The City Of New York | Dna sequencing by synthesis using raman and infrared spectroscopy detection |
US8986629B2 (en) | 2012-02-27 | 2015-03-24 | Genia Technologies, Inc. | Sensor circuit for controlling, detecting, and measuring a molecular complex |
CA2869753A1 (en) | 2012-04-09 | 2013-10-17 | Jingyue Ju | Method of preparation of nanopore and uses thereof |
WO2013188841A1 (en) | 2012-06-15 | 2013-12-19 | Genia Technologies, Inc. | Chip set-up and high-accuracy nucleic acid sequencing |
EP2864502B1 (en) | 2012-06-20 | 2019-10-23 | The Trustees of Columbia University in the City of New York | Nucleic acid sequencing by nanopore detection of tag molecules |
US9605309B2 (en) | 2012-11-09 | 2017-03-28 | Genia Technologies, Inc. | Nucleic acid sequencing using tags |
US9759711B2 (en) | 2013-02-05 | 2017-09-12 | Genia Technologies, Inc. | Nanopore arrays |
WO2014165267A2 (en) * | 2013-03-12 | 2014-10-09 | Counsyl, Inc. | Systems and methods for prenatal genetic analysis |
DK2970356T3 (en) | 2013-03-15 | 2018-08-27 | Illumina Cambridge Ltd | Modified nucleosides or nucleotides |
WO2014144883A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of Columbia University In The City Of New York | Raman cluster tagged molecules for biological imaging |
CN105102627B (en) | 2013-03-15 | 2018-10-19 | 纽约哥伦比亚大学理事会 | Method for detecting a variety of predetermined compounds in sample |
US9765220B2 (en) | 2013-08-22 | 2017-09-19 | Sony Corporation | Water soluble fluorescent or colored dyes and methods for their use |
US9551697B2 (en) | 2013-10-17 | 2017-01-24 | Genia Technologies, Inc. | Non-faradaic, capacitively coupled measurement in a nanopore cell array |
US9567630B2 (en) | 2013-10-23 | 2017-02-14 | Genia Technologies, Inc. | Methods for forming lipid bilayers on biochips |
CA2926138A1 (en) | 2013-10-23 | 2015-04-30 | Genia Technologies, Inc. | High speed molecular sensing with nanopores |
AU2015236392A1 (en) | 2014-03-24 | 2016-10-20 | Genia Technologies, Inc. | Chemical methods for producing tagged nucleotides |
WO2016138457A1 (en) | 2015-02-26 | 2016-09-01 | Sony Corporation | Phenylethynylnaphthalene dyes and methods for their use |
JP6806694B2 (en) | 2015-02-26 | 2021-01-06 | ソニー株式会社 | Water-soluble fluorescent dye or colored dye containing conjugated group |
EP3268050B1 (en) | 2015-03-09 | 2021-07-14 | The Trustees of Columbia University in the City of New York | Pore-forming protein conjugate compositions and methods |
CN107709470B (en) | 2015-05-11 | 2021-01-29 | 索尼公司 | Super bright dimeric or polymeric dyes |
US11085076B2 (en) | 2015-09-28 | 2021-08-10 | The Trustees Of Columbia University In The City Of New York | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis |
US11434377B2 (en) | 2016-04-01 | 2022-09-06 | Sony Corporation | Ultra bright dimeric or polymeric dyes with rigid spacing groups |
AU2017240154B2 (en) | 2016-04-01 | 2021-08-12 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes |
AU2017248165B2 (en) | 2016-04-06 | 2021-08-26 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes with spacing linker groups |
EP3455299B1 (en) | 2016-05-10 | 2024-01-17 | Sony Group Corporation | Compositions comprising a polymeric dye and a cyclodextrin and uses thereof |
JP7527537B2 (en) | 2016-05-10 | 2024-08-05 | ソニーグループ株式会社 | Super-bright polymer dyes with peptide backbones |
RU2018143594A (en) | 2016-05-11 | 2020-06-11 | Сони Корпорейшн | ULTRA-BRIGHT DIMERIC OR POLYMERIC DYES |
CN109661232B (en) | 2016-05-23 | 2023-03-03 | 纽约哥伦比亚大学董事会 | Nucleotide derivatives and methods of use thereof |
EP3464477A1 (en) | 2016-06-06 | 2019-04-10 | Sony Corporation | Ionic polymers comprising fluorescent or colored reporter groups |
US12018159B2 (en) | 2016-07-29 | 2024-06-25 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes and methods for preparation of the same |
EP3596099B1 (en) | 2017-03-06 | 2024-07-24 | Singular Genomics Systems, Inc. | Nucleic acid sequencing-by-synthesis (sbs) methods that combine sbs cycle steps |
WO2018183538A1 (en) | 2017-03-28 | 2018-10-04 | The Trustees Of Columbia University In The City Of New York | 3'-o-modified nucleotide analogues with different cleavable linkers for attaching fluorescent labels to the base for dna sequencing by synthesis |
EP3438649B1 (en) * | 2017-07-31 | 2020-03-11 | Vestel Elektronik Sanayi ve Ticaret A.S. | Identification tag and method of identifying an object |
CN111315415A (en) | 2017-10-05 | 2020-06-19 | 索尼公司 | Programmable polymeric pharmaceuticals |
JP2021503450A (en) | 2017-11-16 | 2021-02-12 | ソニー株式会社 | Programmable polymer drug |
CN111565756A (en) | 2018-01-12 | 2020-08-21 | 索尼公司 | Polymers with rigid spacer groups comprising biologically active compounds |
CN112041680A (en) | 2018-03-19 | 2020-12-04 | 索尼公司 | Use of divalent metals for enhancing fluorescence signal |
KR20200133374A (en) | 2018-03-21 | 2020-11-27 | 소니 주식회사 | Polymeric tandem dyes with linker groups |
CN112313242A (en) | 2018-06-27 | 2021-02-02 | 索尼公司 | Polymeric dyes with deoxyribose-containing linker groups |
WO2020086834A1 (en) | 2018-10-25 | 2020-04-30 | Singular Genomics Systems, Inc. | Nucleotide analogues |
WO2020146397A1 (en) | 2019-01-08 | 2020-07-16 | Singular Genomics Systems, Inc. | Nucleotide cleavable linkers and uses thereof |
WO2021062176A2 (en) | 2019-09-26 | 2021-04-01 | Sony Corporation | Polymeric tandem dyes with linker groups |
EP4397672A1 (en) | 2021-08-31 | 2024-07-10 | FUJIFILM Corporation | Compound and labeled biomaterial using same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4824775A (en) * | 1985-01-03 | 1989-04-25 | Molecular Diagnostics, Inc. | Cells labeled with multiple Fluorophores bound to a nucleic acid carrier |
US5654419A (en) * | 1994-02-01 | 1997-08-05 | The Regents Of The University Of California | Fluorescent labels and their use in separations |
CA2240667A1 (en) * | 1995-12-18 | 1997-06-26 | Washington University | Method for nucleic acid analysis using fluorescence resonance energy transfer |
US5853992A (en) * | 1996-10-04 | 1998-12-29 | The Regents Of The University Of California | Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels |
US5804386A (en) * | 1997-01-15 | 1998-09-08 | Incyte Pharmaceuticals, Inc. | Sets of labeled energy transfer fluorescent primers and their use in multi component analysis |
US5834203A (en) * | 1997-08-25 | 1998-11-10 | Applied Spectral Imaging | Method for classification of pixels into groups according to their spectra using a plurality of wide band filters and hardwire therefore |
DE60044030D1 (en) * | 1999-10-08 | 2010-04-29 | Robert C Leif | MARKER COMPLEXES OF CONJUGATED POLYMERS |
-
2001
- 2001-09-11 CA CA002421582A patent/CA2421582A1/en not_active Abandoned
- 2001-09-11 EP EP01968905A patent/EP1322785A4/en not_active Withdrawn
- 2001-09-11 JP JP2002527323A patent/JP2004508838A/en not_active Withdrawn
- 2001-09-11 AU AU8911101A patent/AU8911101A/en active Pending
- 2001-09-11 WO PCT/US2001/028967 patent/WO2002022883A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2004508838A (en) | 2004-03-25 |
EP1322785A1 (en) | 2003-07-02 |
EP1322785A4 (en) | 2005-11-09 |
AU8911101A (en) | 2002-03-26 |
WO2002022883A1 (en) | 2002-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060057565A1 (en) | Combinatorial fluorescence energy transfer tags and uses thereof | |
US6627748B1 (en) | Combinatorial fluorescence energy transfer tags and their applications for multiplex genetic analyses | |
CA2421582A1 (en) | Combinatorial fluorescence energy transfer tags and uses thereof | |
US6258539B1 (en) | Restriction enzyme mediated adapter | |
US9404155B2 (en) | Alternative nucleic acid sequencing methods | |
Tong et al. | Combinatorial fluorescence energy transfer tags for multiplex biological assays | |
US5824481A (en) | DNA analyzing method | |
US7371520B2 (en) | Methods and apparati using single polymer analysis | |
US5427911A (en) | Coupled amplification and sequencing of DNA | |
US10072287B2 (en) | Methods of targeted sequencing | |
US20030235854A1 (en) | Methods for analyzing a nucleic acid | |
US20050123944A1 (en) | Methods and compositions related to the use of sequence-specific endonucleases for analyzing nucleic acids under non-cleaving conditions | |
JPH03502041A (en) | Rapid DNA and RNA sequencing method | |
JPH08211050A (en) | Method for detecting arrangement of specified nucleic acid | |
JPH07505529A (en) | Probe compositions and methods | |
JP2004507230A (en) | Polynucleotide sequence assay | |
EP2956550B1 (en) | Enhanced probe binding | |
EP1151136A1 (en) | Method for detecting variant nucleotides using arms multiplex amplification | |
JP4297966B2 (en) | Novel measurement method of nucleic acid by using labeled nucleotide | |
CN109689883A (en) | Method for connecting cell constituent and matrix | |
Tong et al. | Combinatorial fluorescence energy transfer tags: New molecular tools for genomics applications | |
JP4276897B2 (en) | Novel measurement method of nucleic acid by using labeled nucleotide | |
Lopez-Crapez et al. | Detection of K-ras Mutations by a Microelectronic DNA Chip | |
Du et al. | Minisequencing on functionalised self-assembled monolayer as a simple approach for single nucleotide polymorphism analysis of cattle | |
Lakowicz | DNA technology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |